Document:

Exhibit 10.4

 

COMMON
STOCK PURCHASE AGREEMENT

 

THIS
COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of October 8, 2020, by and between Smart Repair
Pro, Inc., a private corporation incorporated under the laws of the State of California (“Pro”), Purex Inc.,
a corporation incorporated under the laws the State of California (“Purex”)(Pro together with Purex, the “Companies”),
the stockholders of the Companies detailed in Schedule 1 attached hereto (the “Pro Stockholder”, the
“Purex Stockholders” respectively, and together the “Stockholders”) and Vicky Hacmon, ID
033847799 of 112 Rokach Street, Ramat Gan, Israel (the “Manager”) on the one hand, and Medigus Ltd., a public
company incorporated under the laws of the State of Israel of 7A Industrial Park, P.O. Box 3030, Omer, 8496500 Israel (the “Purchaser”)
on the other hand.

 

The
parties hereby agree as follows:

 

1. Purchase
and Sale of Common Stock.

 

1.1 Purchase
and Issuance of Common Stock.

 

(a) Companies
Valuation. The valuation used for the purpose of determining the purchase price for the Pro Common Stock and the Purex Common
Stock (as each are defined herein), shall be calculated on a joint basis, and shall be equal to; (A) the Companies consolidated
seller discretionary earnings, calculated as the Companies EBITDA (as reflected in the Companies consolidated income statement
for the period ended December 31, 2020 or the “Determination Period”), plus general and administrative
expenses (including Manager’s compensation expenses) and research and development expenses relating to the development of
new products incurred during the Determination Period (the “SDE”); multiplied by (B) 3.5; minus
(C) the outstanding Stockholders Loan (as defined herein)(the “Companies Valuation”). The Companies Valuation
shall be allocated among the Companies such that Pro’s valuation shall equal 88% of the Companies Valuation (the “Pro
Portion” and the “Pro Valuation” respectively) and Purex’s valuation shall be equal to 12% of
the Companies Valuation (the “Purex Portion” and the “Purex Valuation” respectively). The
Companies target SDE for the annual period ended December 31, 2020 shall be $1,000,000 (the “SDE Target”).

 

(b) Subject
to the terms and conditions of this Agreement, the Purchaser agrees to invest $1,100,000 in Pro (the “Pro Investment Amount”)
in consideration for the issuance by Pro at the Closing (as defined below) of 5,572 shares of Pro common stock (the “Pro
Primary Shares” and “Pro Common Stock” respectively) at a price per share for each Pro Primary Share
of $197.4107, reflecting a pre-money valuation on a fully diluted basis equal to the Pro Valuation, calculated based on the SDE
Target (the “Pro PPS”).

 

(c) Subject
to the terms and conditions of this Agreement, the Purchaser agrees to invest $150,00 in Purex (the “Purex Investment
Amount”) in consideration for the issuance by Purex at the Closing (as defined below) of 557 Purex common stock (the
“Purex Primary Shares” and the “Purex Common Stock” respectively) at a price per share of
Purex Common Stock of $269.1964, reflecting a pre-money valuation on a fully diluted basis equal to the Purex Valuation, calculated
based on the SDE Target (the “Purex PPS”). The shares of Pro Primary Shares together with the Purex Primary
Shares issued to the Purchaser pursuant to this Agreement shall be referred to in this Agreement as the “Primary Shares.”
The Pro Investment Amount together with the Purex Investment Amount shall be referred to in this Agreement as the “Investment
Amount”).

 

     

     

    

 

1.2 Post-Closing
Adjustment.

 

(a) Within
three days of their approval and in any event as soon as practicable following the end of the Determination Period, the Companies
shall provide Purchaser with each of the Companies’s respective financial statements (including statement of income, balance
sheet and statement of cash flows) relating to the Determination Period, signed and certified by the Companies’ officers
(the “Determination Period Financials”). The Determination Period Financials shall be prepared in accordance
with generally accepted accounting principles.

 

(b) In
the event that the Companies actual SDE, as reflected in the Determination Period Financials (the “Actual SDE”)
is lower than the SDE Target, then the Companies Valuation shall be recalculated based on the formula included in Section ‎1.1(a)
(the “Adjusted Companies Valuation”) and the Pro Valuation, Pro PPS, Purex Valuation and Purex PPS shall be
adjusted accordingly (the “Adjustment”, the “Adjusted Pro Valuation”, the “Adjusted
Pro PPS” the “Adjusted Purex Valuation” and the “Adjusted Purex PPS” respectively).
For the avoidance of doubt, the Closing Inventory shall remain unchanged in the event of an Adjustment.

 

(c) Following
the Adjustment, each of the Companies shall issue to the Purchaser additional shares of Purex and Pro as follows:

 

(i) Pro
shall issue to the Purchaser such number of additional Pro Common Stock equal to (x) the number of Pro Primary Shares that would
have been issued to the Purchaser based on Adjusted Pro PPS; less (y) the number of Pro Primary Shares actually issued to
Purchaser upon the Closing (the “Pro Adjustment Shares”). The percentage received by dividing the Pro Adjustment
Shares by Pro’s issued outstanding share capital on a fully diluted basis shall be referred to herein as the “Pro
Adjustment Percentage”.

 

(ii) Purex
shall issue to the Purchaser such number of additional Purex Common Stock equal to (x) the number of Purex Primary Shares that
would have been issued to the Purchaser based on the Adjusted Purex PPS; less (y) the number of Purex Primary Shares issued
to Purchaser upon the Closing (the “Purex Adjustment Shares”). The percentage received by dividing the Purex
Adjustment Shares by Purex’s issued outstanding share capital on a fully diluted basis shall be referred to herein as the
“Purex Adjustment Percentage”;

 

(d) For
the avoidance of doubt, in the event that the Actual SDE is equal to or exceeds the SDE Target, no adjustment shall be affected
pursuant to this Section ‎1.2

 

1.3 Secondary
Sale of Common Stock.

 

(a) Simultaneously
with the Closing, Purchaser or its Affiliate shall purchase from the Pro Stockholder additional Pro Common Stock (the “Pro
Secondary Shares”), such that the Pro Secondary Shares and the Pro Primary Shares combined shall constitute 50.01% of
Pro’s issued and outstanding share capital on a fully diluted basis immediately after the Closing (the “Pro Post-Closing
Holdings”) or such closest attainable percentage. In the event that an Adjustment is affected following receipt by Purchaser
of the Determination Period Financials, Pro Stockholder shall have the right to repurchase from Purchaser, for no consideration,
such number of Pro Secondary Shares constituting the Pro Adjustment Percentage (the “Pro Repurchase Right” and
the “Pro Repurchase Shares” respectively).

 

    2

     

    

 

(b) Simultaneously
with the Closing, Purchaser or its Affiliate shall purchase from the Purex Stockholders additional Purex Common Stock (the “Purex
Secondary Shares”), such that the Purex Secondary Shares and the Purex Primary Shares combined shall constitute 50.01%
of Purex’s issue and outstanding share capital on a fully diluted basis immediately after the closing (the “Purex
Post-Closing Holdings”) or such closest attainable percentage. The Purex Secondary Shares shall be purchased in equal
amounts from each of the Purex Stockholders. In the event that an Adjustment is affected following receipt by Purchaser of the
Determination Period Financials, Purex Stockholders shall have the right to repurchase from Purchaser, for no consideration, such
number of Purex Secondary Shares constituting the Purex Adjustment Percentage (the “Purex Repurchase Right”
and the “Purex Repurchase Shares” respectively). Each Purex Stockholder shall have an equal Purex Repurchase
Right to an equal number of Purex Repurchase Shares. The Pro Secondary Shares and the Purex Secondary Shares shall be referred
to in this Agreement as the “Secondary Shares”.

 

(c) In
the event that the Purex Repurchase Right and Pro Repurchase Right is exercised, the Parties shall take all such actions required
in order to affect the repurchase rights and duly transfer the Purex Repurchase Shares and Pro Repurchase Shares back to the Stockholders
in accordance with the terms contained herein.

 

(d) In
consideration for the Secondary Shares, Purchaser shall pay the Stockholders as follows:

 

(i) Upon
Closing, Purchaser shall pay the Stockholders aggregate cash consideration of $150,000 (the “Cash Consideration”),
allocated among the Pro Stockholder and Purex Stockholders in accordance with the Pro Portion and the Purex Portion, with the Purex
Portion of the Cash Consideration to be allocated among each Purex Stockholder in accordance with their pro rata portion of the
Purex Secondary Shares.

 

(ii) Post-Closing
and following the receipt by Purchaser of the Determination Period Financials, the implementation of the Adjustment and exercise
of the Purex and Pro Repurchase Right (if applicable), Purchaser shall issue to the Stockholders restricted American Depositary
Shares of Purchaser (“ADSs”) as follows:

 

(1) The
price per each Pro Secondary Shares shall calculated by dividing $440,000 by the number of Pro Secondary Shares (the “Pro
Secondary PPS”). In consideration for the Pro Secondary Shares, Purchaser shall issue to the Pro Stockholder ADSs of
US Dollar value equal to (x) the number of Pro Secondary Shares; minus (y) the number of Pro Repurchase shares; together
multiplied by the (z) Pro Secondary PPS (the “Pro ADS Consideration”). The price per ADS used in order
to calculate the number of ADSs issued as Pro ADS Consideration shall be equal to the higher of (i) $1, or (ii) the 60 day closing
average of the ADSs on the Nasdaq Capital Market (the “ADS Valuation”).

 

(2) The
price per each Purex Secondary Shares shall be calculated by dividing $60,000 by the number of Purex Secondary Shares (the “Purex
Secondary PPS”). In consideration for the Purex Secondary Shares, Purchaser shall issue to the Purex Stockholders ADSs,
of US Dollar value equal to (x) the number of Purex Secondary Shares; minus (y) the number of Purex Repurchase Shares; together
multiplied by the (z) Purex Secondary PPS (the “Purex ADS Consideration”). The price per ADS used in
order to calculate the number of ADSs issued as Purex ADS Consideration shall be based on the ADS valuation.

 

1.4 Milestone
Payments. The Stockholders shall be entitled to issuance of additional ADSs subject to achievement of the following milestones,
in accordance with the following allocation all in accordance with the term contained herein. As a condition to the issuance of
any ADS Portion (as defined herein), Stockholders will, prior to the planned date of issuance of such ADS Portion (the “ADS
Portion Issuance Date”), provide Purchaser with an execute addendum to this Agreement, attesting that the Stockholders
representations and warranties included in Sections ‎6.6 (Restricted Securities),
‎6.7 (Legends), ‎6.8 (Purchase Entirely
for Own Account), ‎6.9 (Accredited Investor), ‎6.10
(Foreign Investors) and ‎6.11 (No General Solicitation) are true and correct
in all respects as of the applicable ADS Portion Issuance Date.

 

    3

     

    

 

(a) H1
2021 Milestone:

 

(i) Within
three days of their approval and in any event as soon as practicable following the end of the financial period ended June 30, 2021
(“H1 2021 Period”), the Companies shall provide Purchaser with each of the Companies’ respective financial
statements (including statement of income, balance sheet and statement of cash flows) relating to the H1 2021 Period, signed and
certified by the Companies’ officers (the “H1 2021 Financials”). The H1 2021 Financials shall be prepared
in accordance with generally accepted accounting principles.

 

(ii) In
the event that the Companies SDE for H1 2021, in accordance with the H1 2021 Financials exceeds $600,000, the Stockholders shall
be jointly entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation (the “H1 2021
Milestone” and “H1 2021 Milestone ADSs” respectively). Purchaser shall issue to the Pro Stockholder
and the Purex Stockholders (with the Purex Portion divided equally among the Purex Stockholders) their respective portion of the
H1 2021 Milestone ADSs in accordance with the Pro Portion and the Purex Portion.

 

(b) 2021
Annual Milestone:

 

(i) Within
three days of their approval and in any event as soon as practicable following the end of the financial period ended December 31,
2021 (“2021 Annual Period”), the Companies shall provide Purchaser with each of the Company’s respective
financial statements (including statement of income, balance sheet and statement of cash flows) relating to 2021 Annual Period,
signed and certified by the Companies’ officers (the “2021 Annual Financials”). The 2021 Annual Financials
shall be prepared in accordance with generally accepted accounting principles.

 

(ii) In
the event that the Companies SDE for 2021 Annual Period, in accordance with the 2021 Annual Financials exceeds $1,200,000, the
Stockholders shall be jointly entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation
(the “2021 Annual Milestone” and “2021 Annual Milestone ADSs” respectively). Purchaser shall
issue to the Pro Stockholder and the Purex Stockholder their respective portion of the 2021 Annual Milestone ADSs in accordance
with the Pro Portion and the Purex Portion (with the Purex Portion to be divided equally among the Purex Stockholders. In the event
that the 2021 Annual Milestone is achieved, and the H1 2021 Milestone was not, the Stockholders shall also be entitled to receive
the H1 2021 Milestone ADSs in addition to the 2021 Annual Milestone ADSs.

 

(iii) The
Pro ADS Consideration, Purex ADS Consideration, H1 2021 Milestone ADSs and 2021 Annual Milestone ADSs shall be referred to herein
individually as a “ADS Portion” and collectively be referred to as the “ADS Consideration”.

 

(iv) Set
Off. Purchaser shall be entitled to offset from any Portion of the ADS Consideration that becomes due and payable the following
amounts: (i) any amount of Losses that are indemnifiable by an Indemnitor under this Agreement; and (ii) the aggregate of all claimed
amounts under any issued Claim Notice existing as of the time of such payment.

 

    4

     

    

 

1.5 Restriction
on Resale of the ADS Consideration.

 

(a) During
the six (6) months following the cessation of any statutory restriction period applicable to the resale of the ADSs constituting
each ADS Portion of the ADS Consideration, the Stockholders shall not sell ADSs in excess of 25% of such ADS Portion.

 

(b) During
the period commencing six (6) months following the cessation of any statutory restriction applicable to each ADS Portion, such
ADS Portion may be freely resold by the Stockholders in accordance with applicable law, provided that no more than 10% of each
respective ADS Portion be traded in a single trading day.

 

2. Financing
Arrangements.

 

2.1 Stockholder
Loans. Purchaser and the Stockholders hereby acknowledge and agree that the Companies ongoing capital requirements shall be
financed by the Stockholders and Purchaser by way of stockholder loans, upon terms mutually agreed between the Parties. Within
fourteen (14) days following the Closing, Purchaser and the Stockholders shall each extend a loan of principle amount equal to
$250,000 in accordance with the terms of the loan agreement provided by Purchaser (the “Stockholder Financing”
and the “Loan Agreement” respectively). If the Companies require additional financing, the Companies shall submit
notice to Purchaser and the Stockholders, detailing the required amount and use of proceeds. Purchaser and the Stockholders shall
extend a stockholder loan covering the requested amount, up to an aggregate cap of $1,000,000, on a 60/40 basis respectively.

 

2.2 Additional
Financing. Purchaser may, upon its sole discretion, provide the Companies with additional financing of up to a principle amount
of $1 million, in order to finance the acquisition of additional online Amazon stores (the “Acquisition Financing”)
provided that such Acquisition Financing shall constitute 80% of the applicable acquisition cost, with the remaining 20% to be
financed by the Stockholders. The Acquisition Financing shall bear interest and shall be secured by a first degree fixed charge
upon the Companies online stores, a first degree fixed charge upon the Common Stock held by the Stockholders and a floating charge
over the Companies’ available cash and cash equivalents and shall be extended subject to the execution of financing and pledge
agreements in the form and substance acceptable to Purchaser . If Acquisition Financing is extended, such Acquisition Financing
and any interest accrued thereon shall be repaid prior in preference to any dividend distribution and any other indebtedness of
the Companies.

 

3. Manager
Arrangements.

 

3.1 Employment.
The Manager shall enter into an employment agreement with Pro in accordance with the Offer Letter provided by Purchaser, pursuant
to which Manager will invest his full efforts and time to Pro’s activities and operations (the “Employment Agreement”).
The Employment Agreement shall provide for certain equity incentives to be determined in accordance with Purchaser’s share
incentive plan.

 

3.2 Non-Compete
& Non-Solicitation Undertaking. The Manager shall sign a non compete and non solicitation undertaking in a form acceptable
to Purchaser (the “Manager Undertaking”), which shall include an acknowledgment that he is a beneficiary of
the ADS Consideration and that execution by the Manager of the Manager Undertaking and fulfillment of his obligations thereunder
is a material inducement to the Purchaser’s obligations under this Agreement.

 

    5

     

    

 

4. Closing;
Delivery.

 

4.1 The
purchase and sale of the Primary Shares and the Secondary Shares shall take place remotely via the exchange of documents and signatures,
at such time and place as the Companies and the Purchaser mutually agree upon, orally or in writing (which time and place are designated
as the “Closing”). The Closing shall be subject to the condition included in Sections ‎8
and ‎9 below, which conditions shall be deemed to take place simultaneously and no transaction
contemplated therein shall be deemed to have been completed or document deemed to have been delivered until all of the transactions
have been completed and all of the documents have been delivered.

 

4.2 At
the Closing, the Companies and the Stockholders shall deliver to the Purchaser a certificate representing the Primary Shares and
Secondary Shares being purchased by the Purchaser at the Closing against payment of the Investment Amount therefor, by wire transfer
to a bank account designated by the Companies. For the avoidance of doubt, the Portions of the ADS Consideration shall be transferred
post-Closing all in accordance with the terms contained herein.

 

4.3 
Use of Proceeds. The Companies will use the proceeds from the sale of the Primary Shares for the repayment of outstanding
loans extended by Stockholders of an aggregate amount of $1,256,697 (the “Stockholder Loan”). Notwithstanding
the above, the Companies shall retain $100,000 of the Investment Amount for a period of twelve (12) months following the Closing
for the purpose of covering any undisclosed liabilities of the Companies.

 

4.4 Defined
Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed
to have the meanings set forth or referenced below.

 

(a) “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under
common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee
of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one
(1) or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser
with, such Person.

 

(b) “Code”
means the Internal Revenue Code of 1986, as amended.

 

(c) “Companies’
Intellectual Property” means all patents, patent applications, registered and unregistered trademarks, trademark applications,
registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information
and proprietary rights and processes, software, similar or other intellectual property rights, subject matter of any of the foregoing,
tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and in any and all such cases that
are owned or used by the Companies in the conduct of the Companies’ business as now conducted and as presently proposed to
be conducted.

 

(d) “Indemnification
Agreement” means an agreement between the Companies and the directors designated by the Purchaser to serve as members
of the board of directors of each of the Companies, to be elected pursuant to the Voting Agreements, dated as of the date of the
Closing, in the form acceptable to Purchaser.

 

(e) “Investors’
Rights Agreements” means the agreements among the Companies, the Stockholders and the Purchaser dated as of the date
of the Closing, in the form agreed upon between the Parties.

 

(f) “Key
Employee” means the Manager and any employee or consultant who either alone or in concert with others develops, invents,
programs or designs any Company Intellectual Property.

 

    6

     

    

 

(g) “Knowledge”
including the phrase “to the Companies’ knowledge” shall mean the actual knowledge after reasonable investigation
and assuming such knowledge as the individual would have as a result of the reasonable performance of his or her duties in the
ordinary course of the Manager.

 

(h) “Material
Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial
condition, property, prospects or results of operations of the Company.

 

(i) “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

(j) “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(k) “Transaction
Agreements” means this Agreement, the Investors’ Rights Agreements, the Voting Agreement, the Employment Agreement,
the Manager Undertaking, the Indemnification Agreements and the Loan Agreement.

 

(l) “Voting
Agreements” means the agreements among the Companies, the Purchaser and the Stockholders, dated as of the date of the
Closing, in the forms agreed upon between the Parties.

 

5. Representations
and Warranties of the Companies. The Companies hereby represent and warrant to the Purchaser that, except as set forth on the
Disclosure Schedule attached as Exhibit A to this Agreement, which exceptions shall be deemed to be part of the representations
and warranties made hereunder, the following representations are true and complete as of the date of the Closing, except as otherwise
indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections contained
in this Section ‎5, and the disclosures in any section of the Disclosure Schedule shall qualify other sections in this
Section ‎5 only to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable
to such other sections and a specific reference to such other section.

 

5.1 Organization,
Good Standing, Corporate Power and Qualification. The Companies are corporations duly organized, validly existing and in good
standing under the laws of the State of California and have all requisite corporate power and authority to carry on its business
as now conducted and as presently proposed to be conducted. The Companies are duly qualified to transact business and is in good
standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

5.2 Capitalization.

 

(a) The
authorized capital of the Companies consists, immediately prior to the Closing, of:

 

(i) With
respect to Pro, 10,000 shares of common stock, 10,000 shares of which are issued and outstanding immediately prior to the Closing
(the “Pro Common Stock”), and with respect to Purex, 1,000 shares of common stock (“Purex Common Stock”),
1,000 shares of which are issued and outstanding immediately prior to the Closing (Purex Common Stock together with Pro Common
Stock, the “Common Stock”). All of the outstanding shares of Common Stock have been duly authorized, are fully
paid and nonassessable and were issued in compliance with all applicable federal and state securities laws.

 

    7

     

    

 

(ii) The
Companies hold no Preferred Stock in its treasury.

 

(b) Reserved.

 

(c) Section
‎(c) of the Disclosure Schedule sets forth the capitalization of the Companies immediately following the Closing. There
are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar
rights) or agreements, orally or in writing, to purchase or acquire from the Companies any shares of Common Stock or any securities
convertible into or exchangeable for shares of Common Stock.

 

(d) The
Companies have obtained valid waivers of any rights by other parties to purchase any of the Primary Shares or Secondary Shares
covered by this Agreement.

 

5.3 Subsidiaries.
The Companies do not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust,
joint venture, limited liability company, association, or other business entity. Except as described in Section ‎5.3 of the
Disclosure Schedule, the Companies are not participants, jointly or severally, in any joint venture, partnership or similar arrangement.

 

5.4 Authorization.
All corporate action required to be taken by the Companies’ respective board of directors, Stockholders and Manager in order
to authorize the Companies to enter into the Transaction Agreements, to issue the Primary Shares and transfer the Secondary Shares
at the Closing has been taken prior to the Closing. All action on the part of the officers of the Companies necessary for the execution
and delivery of the Transaction Agreements, the performance of all obligations of the Companies under the Transaction Agreements
to be performed as of the Closing, and the issuance and delivery of the Primary Shares and transfer of the Secondary Shares has
been taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Companies, the Stockholders and
the Manager, shall constitute valid and legally binding obligations of the Companies, Stockholders and Manager, enforceable against
such in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies, or (iii) to the extent the indemnification provisions contained in the Indemnification Agreement may be limited
by applicable federal or state securities laws.

 

5.5 Valid
Issuance of Shares. The Primary Shares, when issued, sold and delivered in accordance with the terms and for the consideration
set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than
restrictions on transfer under the Transaction Agreements and applicable state and federal securities laws. Assuming the accuracy
of the representations of the Purchasers in Section ‎6 of this Agreement and subject to the filings described in the
Voting Agreement, the Primary Shares will be issued in compliance with all applicable federal and state securities laws.

 

5.6 Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section ‎6 of
this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing
with, any federal, state or local governmental authority is required on the part of the Company in connection with the consummation
of the transactions contemplated by this Agreement, except for the filing of the Restated Certificates, which will have been filed
as of the Closing.

 

    8

     

    

 

5.7 Litigation.
There is no claim, action, suit, proceeding, arbitration, complaint, charge or to the Companies Knowledge, investigation pending
or currently threatened (i) against the Companies or any officer, director or Key Employee of the Companies; or (ii) to that questions
the validity of the Transaction Agreements or the right of the Companies to enter into them, or to consummate the transactions
contemplated by the Transaction Agreements; or (iii) to the Companies’ knowledge, that would reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect. Neither the Companies nor, to the Companies’ knowledge,
any of its officers, directors or Key Employees is a party or is named as subject to the provisions of any order, writ, injunction,
judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or Key Employees, such
as would affect the Companies). There is no action, suit, proceeding or investigation by the Companies pending or which the Companies
intend to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened
in writing (or any basis therefor known to the Companies) involving the prior employment of any of the Companies’ employees,
their services provided in connection with the Companies’ business, any information or techniques allegedly proprietary to
any of their former employers or their obligations under any agreements with prior employers.

 

5.8 Intellectual
Property.

 

(a) The
Companies own or possess or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property
without any known conflict with, or infringement of, the rights of others, including prior employees or consultants. The Companies
have not received any communications alleging that the Companies have violated, or by conducting their business, would violate
any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or
processes of any other Person.

 

(b) No
product or service marketed or sold (or proposed to be marketed or sold) by the Companies violates or will violate any license
or infringes or will infringe any intellectual property rights of any other party.

 

(c) Other
than with respect to commercially available software products under standard end-user object code license agreements, and except
as described in Section ‎5.8‎(c) of the Disclosure Schedule, there are no outstanding options, licenses, agreements, claims,
encumbrances or shared ownership interests of any kind relating to the Companies Intellectual Property, nor are the Companies bound
by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade
names, copyrights, trade secrets, software, licenses, information, proprietary rights and processes of any other Person.

 

(d) The
Companies have obtained and possess valid licenses to use all of the software programs present on the computers and other software-enabled
electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the
Companies’ business.

 

(e) Each
employee and consultant has assigned to the Companies all intellectual property rights he or she owns that are related to the Companies’
business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely
or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship
with the Companies that (i) relate, at the time of conception, reduction to practice, development, or making of such intellectual
property right, to the Companies’ business as then conducted or as then proposed to be conducted, (ii) were developed on
any amount of the Companies’ time or with the use of any of the Company’s equipment, supplies, facilities or information
or (iii) resulted from the performance of services for the Companies. It will not be necessary to use any inventions of any of
its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Companies, including
prior employees or consultants.

 

    9

     

    

 

(f) Section ‎5.8(f)
of the Disclosure Schedule lists all patents, patent applications, trademarks, trademark applications, service marks, service mark
applications, tradenames, copyrights, and licenses to and under any of the foregoing, in each case owned by the Companies.

 

(g) The
Companies have not embedded, used or distributed any open source, copyleft or community source code (including but not limited
to any libraries or code, software, technologies or other materials that are licensed or distributed under any General Public License,
Lesser General Public License or similar license arrangement or other distribution model described by the Open Source Initiative
at www.opensource.org, collectively “Open Source Software”) in connection with any of its products or services
that are generally available or in development in any manner that would materially restrict the ability of the Company to protect
its proprietary interests in any such product or service or in any manner that requires, or purports to require (i) any of
the Companies Intellectual Property (other than the Open Source Software itself) be disclosed or distributed in source code form
or be licensed for the purpose of making derivative works; (ii) any restriction on the consideration to be charged for the
distribution of any Companies Intellectual Property; (iii) the creation of any obligation for the Companies with respect to
Companies Intellectual Property owned by the Companies, or the grant to any third party of any rights or immunities under Companies
Intellectual Property owned by the Companies; or (iv) any other limitation, restriction or condition on the right of the Companies
with respect to its use or distribution of any Companies Intellectual Property.

 

(h) No
government funding, facilities of a university, college, other educational institution or research center, or funding from third
parties was used in the development of any Companies Intellectual Property. No Person who was involved in, or who contributed to,
the creation or development of any Company Intellectual Property, has performed services for the government, university, college,
or other educational institution or research center in a manner that would affect Companies’ rights in the Companies Intellectual
Property.

 

5.9 Compliance
with Other Instruments. The Companies are not in violation or default (i) of any provisions of their Restated Certificates
or Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under
any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed on
the Disclosure Schedule, or (v) of any provision of federal or state statute, rule or regulation applicable to the Companies, the
violation of which would have a Material Adverse Effect. The execution, delivery and performance of the Transaction Agreements
and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation or be
in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under any such provision,
instrument, judgment, order, writ, decree, contract or agreement; or (ii) an event which results in the creation of any lien, charge
or encumbrance upon any assets of the Companies’ or the suspension, revocation, forfeiture, or nonrenewal of any material
permit or license applicable to the Companies’.

 

5.10 Agreements;
Actions.

 

(a) Except
for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(a) of the Disclosure Schedule there are no agreements,
understandings, instruments, contracts or proposed transactions to which the Companies are a party or by which it is bound that
involve (i) obligations (contingent or otherwise) of, or payments to, the Companies in excess of $50,000, (ii) the license
of any patent, copyright, trademark, trade secret, software or other proprietary right to or from the Companies, (iii) the
grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit the Companies’
exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Companies
with respect to infringements of proprietary rights.

 

    10

     

    

 

(b) Except
for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(b), the Companies have not (i) declared
or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock,
(ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $100,000 in
the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for business expenses, or (iv) sold,
exchanged or otherwise disposed of any of its assets or rights, other than in the ordinary course of business. For the purposes
of ‎(a) and ‎(b) of this Section ‎5.10, all indebtedness, liabilities, agreements, understandings, instruments,
contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe are affiliated
with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such section.

 

(c) The
Companies are not guarantors or indemnitors of any indebtedness of any other Person.

 

5.11 Certain
Transactions.

 

(a) Other
than (i) standard employee benefits generally made available to all employees, standard employee offer letters and Confidential
Information Agreements (as defined below), (ii) standard director and officer indemnification agreements approved by the board
of directors of the Companies, (iii) the purchase of shares of the Companies’ capital stock, in each instance, approved in
the written minutes of the board of directors (previously provided to the Purchasers or their respective counsel), and (iv) the
Transaction Documents, there are no agreements, understandings or proposed transactions between the Companies and any of its officers,
directors, consultants or Key Employees, or any Affiliate thereof.

 

(b) Other
than as disclosed is Section ‎5.11(b) of the Disclosure Schedule, the Companies are not indebted, directly or indirectly, to
any of its directors, officers or employees or to their respective spouses or children or to any Affiliate of any of the foregoing,
other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation
expenses and for other customary employee benefits made generally available to all employees. None of the Companies’ directors,
officers or employees, or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly,
indebted to the Companies or, have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable
or familial relationship with any of the Companies’ customers, suppliers, service providers, joint venture partners, licensees
and competitors, (ii) direct or indirect ownership interest in any firm or corporation with which the Companies are affiliated
or with which the Companies have a business relationship, or any firm or corporation which competes with the Companies.

 

5.12 Rights
of Registration and Voting Rights. The Companies are not under any obligation to register under the Securities Act any of its
currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities.
Except as contemplated in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the
voting of capital shares of the Companies.

 

5.13 Property.
The property and assets that the Companies own are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances,
except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in
the ordinary course of business and do not materially impair the Companies’ ownership or use of such property or assets.
With respect to the property and assets it leases, the Companies are in compliance with such leases and holds a valid leasehold
interest free of any liens, claims or encumbrances other than those of the lessors of such property or assets. The Companies do
not own any real property.

 

    11

     

    

 

5.14 Financial
Statements. The Companies have delivered to the Purchaser their unaudited financial statements for the fiscal year ended December
31, 2019 and its unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of June
30, 2020 (the “Balance Sheet Date”) and for the six-month period ended on the Balance Sheet Date (collectively,
the “Financial Statements”). The Financial Statements have been prepared in accordance with international financial
reporting standards (“IFRS”) applied on a consistent basis throughout the periods indicated. The Financial Statements
fairly present in all material respects the financial condition and operating results of the Company as of the dates, and for the
periods, indicated therein, subject in the case of the unaudited Financial Statements to normal year-end audit adjustments. Except
for the Stockholders Loan, and except as disclosed in Section ‎5.14 of the Disclosure Schedule, the Companies have no liabilities
or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent
to the Balance Sheet Date; (ii) obligations under contracts and commitments incurred in the ordinary course of business; and
(iii) liabilities and obligations of a type or nature not required under IFRS to be reflected in the Financial Statements, which,
in all such cases, individually and in the aggregate would not exceed $100,000. The Companies maintain and will continue to maintain
a standard system of accounting established and administered in accordance with IFRS.

 

5.15 Changes.
Since the Balance Sheet Date there have been no events or circumstances of any kind that have or could reasonably be expected to
result in a Material Adverse Effect.

 

5.16 Employee
Matters.

 

(a) To
the Companies’ knowledge, none of its employees is obligated under any contract (including licenses, covenants or commitments
of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would
materially interfere with such employee’s ability to promote the interest of the Companies or that would conflict with the
Companies’ business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the Companies’
business by the employees of the Companies, nor the conduct of the Companies’ business as now conducted and as presently
proposed to be conducted, will, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a
default under, any contract, covenant or instrument under which any such employee is now obligated.

 

(b) The
Companies are not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries,
commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be
reimbursed to such employees, consultants or independent contractors. The Companies have complied in all material respects with
all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related
to wages, hours, worker classification and collective bargaining. The Companies have withheld and paid to the appropriate governmental
entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of
the Companies and are not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the
foregoing.

 

(c) To
the Companies’ knowledge, no Key Employee intends to terminate employment with the Company or is otherwise likely to become
unavailable to continue as a Key Employee. The Companies do not have a present intention to terminate the employment of any of
the foregoing. The employment of each employee of the Companies is terminable at the will of the Companies. Except as required
by law, upon termination of the employment of any such employees, no severance or other payments will become due. The Companies
have no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the
termination of employment services.

 

    12

     

    

 

(d) The
Companies have not made any representations regarding equity incentives to any officer, employee, director or consultant of the
Companies.

 

(e) Section
‎5.16‎(e) of the Disclosure Schedule includes a list of all current and former employees of the Companies.

 

(f) To
the Companies’ knowledge, none of the Key Employees or directors of the Companies have been (i) subject to voluntary or involuntary
petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar
officer by a court for his or her business or property; (ii) convicted in a criminal proceeding or named as a subject of a pending
criminal proceeding (excluding traffic violations and other minor offenses); (iii) subject to any order, judgment or decree
(not subsequently reversed, suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining
him or her from engaging, or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory,
banking, insurance, or other type of business or acting as an officer or director of a public company; or (iv) found by a
court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading
Commission to have violated any federal or state securities, commodities, or unfair trade practices law, which such judgment or
finding has not been subsequently reversed, suspended, or vacated.

 

5.17 Tax
Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the Companies which have
not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Companies which are
due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable
federal, state, local or foreign governmental agency. The Companies have duly and timely filed all federal, state, county, local
and foreign tax returns or other tax filings required to have been filed by it and there are in effect no waivers of applicable
statutes of limitations with respect to taxes for any year.

 

5.18 Insurance.
The Companies have in full force and effect insurance policies concerning such casualties as would be reasonable and customary
for companies like the Companies sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties
that might be damaged or destroyed.

 

5.19 Employee
Agreements. Each current and former employee, consultant and officer of the Companies has executed an agreement with the Companies
regarding confidentiality and proprietary information (the “Confidential Information Agreements”).

 

5.20 Permits.
The Companies have all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack
of which could reasonably be expected to have a Material Adverse Effect. The Companies are not in default in any material respect
under any of such franchises, permits, licenses or other similar authority.

 

5.21 Amazon
Seller Code of Conduct and Policies. The Companies adhere to and comply with all Amazon policies, agreements, guidelines, and
codes of conduct applicable to the conduct of the Companies’ business (the “Amazon Policies”). The Companies
have not previously violated the Amazon Policies and have not received notice of any such violation.

 

5.22 Corporate
Documents. The Certificate of Incorporation and Bylaws of the Companies as of the date of this Agreement are in the form provided
to the Purchasers.

 

    13

     

    

 

5.23 Foreign
Corrupt Practices Act. Neither the Companies nor any of its directors, officers, employees or agents have, directly or indirectly,
made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign
official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)),
foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official
act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence
to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i),
(ii) and (iii) above in order to assist the Companies or any of its affiliates in obtaining or retaining business for or with,
or directing business to, any person. Neither the Companies nor any of their directors, officers, employees or agents have made
or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained
any funds in violation of any law, rule or regulation. Neither the Company nor any of its officers, directors or employees are
the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA
or any other anti-corruption law (collectively, “Enforcement Action”).

 

5.24 Data
Privacy. In connection with its collection, storage, use and/or disclosure of any information that constitutes “personal
information,” “personal data” or “personally identifiable information” as defined in applicable laws
(collectively “Personal Information”) by or on behalf of the Companies, the Companies are and have been in compliance
with (i) all applicable laws (including, without limitation, laws relating to privacy, data security, telephone and text message
communications, and marketing by email or other channels) in all relevant jurisdictions, (ii) the Companies’ privacy policies
and public written statements regarding the Company’s privacy or data security practices, and (iii) the requirements of any
contract codes of conduct or industry standards, by which the Company is bound. The Companies maintain and have maintained reasonable
physical, technical, and administrative security measures and policies designed to protect all Personal Information owned, stored,
used, maintained or controlled by or on behalf of the Companies from and against unlawful, accidental or unauthorized access, destruction,
loss, use, modification and/or disclosure. The Companies are and have been, to the Companies knowledge, in compliance in all material
respects with all laws relating to data loss, theft and breach of security notification obligations.

 

5.25 Export
Control Laws. The Companies have conducted all export transactions in accordance with applicable provisions of United States
export control laws and regulations, including the Export Administration Regulations, the International Traffic in Arms Regulations,
the regulations administered by the Office of Foreign Assets Control of the U.S. Treasury Department, and the export control laws
and regulations of any other applicable jurisdiction. Without limiting the foregoing: (a) the Companies have obtained all export
licenses and other approvals, timely filed all required filings and has assigned the appropriate export classifications to all
products, in each case as required for its exports of products, software and technologies from the United States and any other
applicable jurisdiction; (b) the Companies are in compliance with the terms of all applicable export licenses, classifications,
filing requirements or other approvals; (c) there are no pending or to the knowledge of the Companies, threatened claims against
the Companies with respect to such exports, classifications, required filings or other approvals; (d) there are no pending investigations
related to the Companies’ exports; and (e) there are no actions, conditions, or circumstances pertaining to the Company’s
export transactions that would reasonably be expected to give rise to any material future claims.

 

5.26 Regulatory
Approvals. The Companies possess all permits, licenses, registrations, certificates, authorizations, orders and approvals from
the appropriate federal, state or foreign regulatory authorities necessary to conduct their business, including all such permits,
licenses, registrations, certificates, authorizations, orders and approvals required by the FDA, EPA or any other federal, state
or foreign agencies or bodies engaged in the regulation of drugs, pharmaceuticals, medical devices, sanitation or biohazardous
materials. The Companies have not received any notice of proceedings relating to the suspension, modification, revocation or cancellation
of any such permit, license, registration, certificate, authorization, order or approval.

 

    14

     

    

 

5.27 Regulations.
The Companies are and have been in compliance with all applicable laws administered or issued by the FDA, EPA or any similar governmental
entity, including the Federal Food, Drug, and Cosmetic Act and all other laws regarding developing, testing, manufacturing, marketing,
distributing or promoting the products of the Companies, or complaint handling or adverse event reporting.

 

5.28 Disclosure.
The Companies have made available to the Purchaser all the information reasonably available to the Companies that the Purchaser
has requested for deciding whether to acquire the Primary Shares and Secondary Shares, including certain of the Company’s
projections describing its proposed business plan (the “Business Plan”). No representation or warranty of the
Companies contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished
to Purchaser at the Closing contains any untrue statement of a material fact or omits to state a material fact necessary in order
to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. The
Business Plan was prepared in good faith; however, the Companies do not warrant that it will achieve any results projected in the
Business Plan. It is understood that this representation is qualified by the fact that the Companies have not delivered to the
Purchaser, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types
of information customarily furnished to purchasers of securities.

 

6. Representation
and Warranties of the Stockholders. Each of the Stockholders herby represents and warrants to the Purchaser, severally and
not jointly, acknowledging that Purchaser is entering the Agreement in reliance thereon, that:

 

6.1 Ownership.
The Stockholders own, beneficially and of record, and have good, valid marketable title to, all the Secondary Shares and no other
person owns, beneficially or of record the Secondary Shares. The Secondary Shares are free and clear of any liens, rights of first
refusal, co-sale rights, sale limitation or pre-emptive rights, except as a result of the transactions contemplated hereunder.
No other person or entity has any power or right, whether shared with any other person or entity, to dispose of the or direct the
disposition, or to vote or direct the voting of the Secondary Shares.

 

6.2 Authority.
The Stockholders have all requisite power and full legal right to execute and deliver this Agreement, and to perform all of their
obligations hereunder. This Agreement and the transactions contemplated hereby have been duly executed and delivered on the part
of the Stockholders, and constitute legal, valid and binding obligations, enforceable against each Stockholder in accordance with
their terms.

 

6.3 No
Conflict. The execution, delivery and performance by the Stockholders of this Agreement and in accordance with its terms, and
the consummation by the Stockholders of the transactions contemplated hereby, will not result (with or without the giving of notice
or the lapse of time or both) in any conflict, violation, breach or default, or the creation of any lien, or the termination, acceleration,
vesting or modification of any right or obligation under or with respect to (a) any judgement, decree, order, statute, rule or
regulation binding on or applicable to the Stockholders; (b) any agreement or instrument to which the Stockholders are party or
by which their assets are bound.

 

6.4 Litigation.
The Stockholders are not aware of any claim, action or proceeding that is pending in any court or before any arbitrator against
the Stockholders with respect to the Secondary Shares or any other Common Stock of the Companies’ held by them.

 

    15

     

    

 

6.5 Upon
full receipt of the ADS Consideration (or such applicable ADSs as the Stockholders shall be entitled to upon achievement of the
H1 2021 Milestone 2021 Annual Milestone), the Stockholders shall have no further rights in or to the Secondary Shares sold thereby.

 

6.6 Restricted
Securities. The Stockholders understands that the ADS Consideration has not been, and will not be, registered under the Securities
Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things,
the bona fide nature of the investment intent and the accuracy of the Stockholders’ representations as expressed herein.
The Stockholders understands that the ADS Consideration is “restricted securities” under applicable U.S. federal and
state securities laws and that, pursuant to these laws, the Stockholders must hold the ADS Consideration indefinitely unless they
are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration
and qualification requirements is available. The Stockholders acknowledge that the Purchaser has no obligation to register or qualify
the ADS Consideration for resale. The Stockholders further acknowledge that if an exemption from registration or qualification
is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding
period for the ADS Consideration, and on requirements relating to the Purchaser which are outside of the Stockholders control,
and which the Purchasers are under no obligation and may not be able to satisfy. The Stockholders understand that this offering
is not intended to be part of the public offering, and that the Stockholders will not be able to rely on the protection of Section
11 of the Securities Act.

 

6.7 Legends.
The Stockholders understand that the ADSs constituting the ADS Consideration may be notated with one or all of the following legends:

 

“THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(a) Any
legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any
legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate,
instrument, or book entry so legended.

 

6.8 Purchase
Entirely for Own Account. This Agreement is made with the Stockholders in reliance upon the Stockholders’ representation
to the Purchaser, which by the Stockholders’ execution of this Agreement, the Stockholders hereby confirm, that the ADS Consideration
to be acquired by the Stockholders will be acquired for investment for the Stockholders’ own account, not as a nominee or
agent, and not with a view to the resale or distribution of any part thereof, and that the Stockholders have no present intention
of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Stockholders further
represents that the Stockholders do not presently have any contract, undertaking, agreement or arrangement with any Person to sell,
transfer or grant participations to such Person or to any third Person, with respect to any of the ADS Consideration.

 

    16

     

    

 

6.9 Accredited
Investor; Non U.S. Person; Investment Experience. The Stockholders acknowledge that they are able to fend for themselves, can
bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable
of evaluating and understanding the merits and risks of the investment in the Purchaser. The Stockholders are either (i) an accredited
investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under
Regulation S promulgated under the Securities Act. To the extent that the Stockholders are non U.S. Persons, Stockholders (x) are
not acquiring the ADS Consideration on account or benefit of any U.S. Person, (y) are not, at the time of execution of the Agreement,
and will not be at the time of the issuance of the ADS Consideration, in the United States and (z) are not a “distributor”
(as defined in Regulation S promulgated under the Securities Act).

 

6.10 Foreign
Investors. If the Stockholders are not a United States person (as defined by Section 7701(a)(30) of the Code), the Stockholders
hereby represent that they have satisfied themselves as to the full observance of the laws of its jurisdiction in connection with
any invitation to subscribe for the ADS Consideration or any use of this Agreement, including (i) the legal requirements within
its jurisdiction for the purchase of the ADS Consideration, (ii) any foreign exchange restrictions applicable to such purchase,
(iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the ADS Consideration. The Stockholders
subscription and payment for and continued beneficial ownership of the ADS Consideration will not violate any applicable securities
or other laws of the Stockholders jurisdiction.

 

6.11 No
General Solicitation. The Stockholders have neither directly or indirectly, including, through a broker or finder (a) engaged
in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the ADS Consideration.

 

7. Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that:

 

7.1 Authorization.
The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser
is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser,
enforceable against such Purchaser in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’
rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies, or (b) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited
by applicable federal or state securities laws.

 

7.2 Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to
the Companies, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Primary Shares
and Secondary Shares to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not
as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present
intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser
further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person
to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. The Purchaser
has not been formed for the specific purpose of acquiring the Primary Shares or the Secondary Shares.

 

7.3 Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs
and the terms and conditions of the offering of the Primary Shares with the Companies’ management. The foregoing, however,
does not limit or modify the representations and warranties of the Companies in Section ‎5 of this Agreement or
the right of the Purchaser to rely thereon.

 

    17

     

    

 

7.4 Restricted
Securities. The Purchaser understands that the Primary Shares and the Secondary Shares have not been, and will not be, registered
under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends
upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations
as expressed herein. The Purchaser understands that the Primary Shares and Secondary Shares are “restricted securities”
under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Primary Shares
and Secondary Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state
authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that
the Companies have no obligation to register or qualify the Primary Shares, or the Secondary Shares for resale. The Purchaser further
acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Primary Shares and Secondary Shares, and
on requirements relating to the Companies which are outside of the Purchaser’s control, and which the Companies are under
no obligation and may not be able to satisfy. The Purchaser understands that this offering is not intended to be part of the public
offering, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act.

 

7.5 No
Public Market. The Purchaser understands that no public market now exists for the Primary Shares and Secondary Shares, and
that the Companies have made no assurances that a public market will ever exist for the Primary Shares and Secondary Shares.

 

7.6 Legends.
The Purchaser understands that the Primary Shares and Secondary Shares may be notated with one or all of the following legends:

 

“THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(a) Any
legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any
legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate,
instrument, or book entry so legended.

 

7.7 Accredited
Investor; Non U.S. Person; Investment Experience. The Purchaser acknowledges that it is able to fend for itself, can bear the
economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating
and understanding the merits and risks of the investment in the Companies. The Purchaser is either (i) an accredited investor as
defined in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under Regulation
S promulgated under the Securities Act. To the extent that the Purchaser is a non U.S. Person, Purchaser (x) is not acquiring the
Primary Shares or Secondary Shares on account or benefit of any U.S. Person, (y) is not, at the time of execution of the Agreement,
and will not be at the time of the issuance of the Primary Shares, in the United States and (z) is not a “distributor”
(as defined in Regulation S promulgated under the Securities Act).

 

    18

     

    

 

7.8 Foreign
Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the Primary Shares or any use of this Agreement, including (i) the legal requirements within its
jurisdiction for the purchase of the Primary Shares and Secondary Shares, (ii) any foreign exchange restrictions applicable
to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and
other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Primary Shares
or the Secondary Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the Primary Shares
and the purchase of the Secondary Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

 

7.9 No
General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners
has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published
any advertisement in connection with the offer and sale of the Primary Shares and Secondary Shares.

 

7.10 Residence.
Purchaser’s office or offices or principal place of business is as identified in the preamble to this agreement.

 

8. Conditions
to the Purchasers’ Obligations at Closing. The obligations of Purchaser
to purchase Primary Shares and the Secondary Shares at the Closing are subject to the fulfillment, on or before such Closing, of
each of the following conditions, unless otherwise waived:

 

8.1 Representations
and Warranties. The representations and warranties of the Companies and the Stockholders contained in Section ‎5
and Section ‎6 shall be true and correct in all respects as of such Closing.

 

8.2 Performance.
The Companies, Stockholders and Manager shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by the Companies, Stockholders and the Manager on
or before such Closing.

 

8.3 Compliance
Certificate. The chief executive officer of the Companies’ shall deliver to the Purchaser at such Closing a certificate
certifying that the conditions specified in Sections ‎8.1 and ‎8.2 have been fulfilled.

 

8.4 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any
state that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares
pursuant to this Agreement shall be obtained and effective as of such Closing.

 

8.5 Opinion
of Company Counsel. The Purchasers shall have received from counsel for the Companies, an opinion, dated as of the Closing,
in the form acceptable to the Purchaser.

 

8.6 Board
of Directors. As of the Closing, the authorized size of the Pro board of directors (the “Pro Board”) shall
be three (3), and the Pro Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Pro Stockholder.
As of the Closing, the authorized size of the Purex board of directors (the “Purex Board”) shall be three (3),
and the Purex Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Purex Stockholders.

 

    19

     

    

 

8.7 Indemnification
Agreement. The Companies shall have executed and delivered the Indemnification Agreements for each of the members of the Pro
Board and Purex Board respectively.

 

8.8 Investors’
Rights Agreement. The Companies and the Stockholders of the Companies shall have executed and delivered the the Investors’
Rights Agreement for each of Pro and Purex.

 

8.9 Voting
Agreement. The Companies and the Stockholders shall have executed and delivered their respective Voting Agreement.

 

8.10 Restated
Certificate. The Companies shall have each adopted and filed their respective restated certificates with the Secretary of State
of California, in the form acceptable to the Purchaser (the “Restated Certificates”) on or prior to the Closing,
which shall continue to be in full force and effect as of the Closing.

 

8.11 Restated
Bylaws. The Companies’ shall have each amended their respective Bylaws on or prior to the Closing, in accordance with
a form acceptable to Purchaser (the “Restated Bylaws”).

 

8.12 Secretary’s
Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate certifying (i)
the Certificate of Incorporation and Bylaws of the Companies as in effect at the Closing, (ii) resolutions of Pro Board and Purex
Board approving the Transaction Agreements and the transactions contemplated under the Transaction Agreements, and (iii) resolutions
of the Stockholders of the Companies approving the Restated Certificates and Restated Bylaws.

 

8.13 Employment
Agreement. The Manager shall have executed and entered the Employment Agreement with Pro on or prior to the Closing with such
Employment Agreement to be in effect as of the Closing.

 

8.14 Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all
documents incident thereto shall be reasonably satisfactory in form and substance to Purchaser, and Purchaser (or its counsel)
shall have received all such counterpart original and certified or other copies of such documents as reasonably requested. Such
documents may include good standing certificates.

 

9. Conditions
of the Companies’ and Stockholder Obligations at Closing. The obligations of the Companies’ and the Stockholder
to sell the Primary Shares and Secondary Shares to the Purchaser at the Closing are subject to the fulfillment, on or before the
Closing, of each of the following conditions, unless otherwise waived:

 

9.1 Representations
and Warranties. The representations and warranties of the Purchaser contained in Section ‎6 shall be true and correct
in all respects as of such Closing.

 

9.2 Performance.
The Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement
that are required to be performed or complied with by Purchaser on or before such Closing.

 

9.3 Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any
state that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares
pursuant to this Agreement shall be obtained and effective as of the Closing.

 

    20

     

    

 

9.4 Investors’
Rights Agreement. Purchaser shall have executed and delivered the Investors’ Rights Agreement for each of the Companies.

 

9.5 Voting
Agreement. Purchaser shall have executed and delivered the Voting Agreement for each of the Companies.

 

10. Indemnification.

 

10.1 Effectiveness;
Survival.

 

(a) Purchaser
has the right to fully rely upon all representations, warranties and covenants of the Companies and Stockholders (as applicable,
severally and not jointly, the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules
attached hereto. Unless otherwise set forth in this Agreement, the representations and warranties of the Companies and Stockholders
contained in or made pursuant to this Agreement shall in no way be affected by any investigation or knowledge of the subject matter
thereof made by or on behalf of Purchaser.

 

(b) The
representations and warranties of the Companies and the Stockholders contained in or made pursuant to this Agreement shall survive
the execution and delivery of this Agreement and the Closing until the earlier of:

 

(c) immediately
prior to the consummation of a Deemed Liquidation Event (as such terms are defined under the Restated Certificates), or

 

(d) (1)
in case of Section 4.8 (Intellectual Property), until the 36th months anniversary of the Closing; (2) in case
of Sections ‎5.1 (Organization), ‎5.2 (Capitalization), ‎5.4 (Authorization), ‎5.5 (Valid
Issuance of Shares), ‎5.6 (Consents) and ‎5.9 (Compliance with Other Instruments) (the representations
and warranties referred to in this clause ‎(d), collectively, the “Fundamental Representations”), until
the expiration of the applicable statute of limitation period; and (3) other than as set forth in clause (1) and (2) above, the
24th months anniversary of the Closing Date; in each case, with respect to any theretofore un-asserted claims as set
forth in clause (c) below;

 

provided, however,
that no limitation shall apply to breach of any representation or warranty which constitutes fraud or willful misrepresentation
by the Companies (as the case may be) (“Fraud”). The applicable survival period shall be referred to, as applicable,
as the “Claims Period”.

 

(e) Except
for Fraud, the Companies and Stockholders shall not have any liability with respect to any breach of representation and warranty,
unless a claim is made hereunder prior to the expiration of the Claims Period for such representation and warranty, in which case
such representation and warranty shall survive as to that claim until the claim has been finally resolved.

 

(f) It
is the intention of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations
and warranties, and this Section ‎(f) constitutes a separate written legally binding agreement among the parties hereto.

 

10.2 Indemnification.

 

(a) Indemnifiable
Losses. The Indemnitor shall indemnify Purchaser (including its shareholders, limited and general partners directors and officers)
(each, an “Indemnitee”) against, and hold each Indemnitee harmless from all claims, actions, suits, settlements,
damages, expenses (including, reasonable legal costs and expenses), losses, diminution of value, or costs sustained or incurred
by such Indemnitees (collectively, “Losses”) resulting from, or arising out of, a breach or misrepresentations
of any of the Indemnitor’s representations, warranties or covenants made in this Agreement, subject to the limitations in
this Section ‎10.2. For the avoidance of doubt, Indemnitors shall indemnify Indemnitee for losses on a joint and not several
basis.

 

    21

     

    

 

(b) Limitations.
The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations, notwithstanding
anything to the contrary in this Agreement, but in addition to any other limitation or condition contained herein; provided,
however, that no such limitation shall apply to Fraud:

 

(c) Other
than in respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate
of Losses equal or exceeds US$50,000, in which case indemnification shall be made from the first dollar amount.

 

(d) Except
for Fraud, the Indemnitor’s liability shall be limited to the aggregate amount of the Investment Amount under the Agreement
at the Closing and the ADS Consideration payable by Purchaser to the Indemnitors, and each Indemnitee shall be entitled to receive
the indemnifiable Loss up to the sum of the Investment Amount as of the Closing and the ADS Consideration actually payable thereafter.

 

(e) Claims
Notice; Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder it shall
give the Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable
detail the facts and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor
informed, in all material respects, with respect thereto. In the event that such Claims Notice results from a third party claim
against the Indemnitee, such Indemnitee shall promptly upon becoming aware of the commencement of proceedings by such third party
provide the Indemnitor with the Claims Notice and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s
expense) with counsel mutually satisfactory to the parties; provided, however, that the Indemnitees shall have the right
to retain their own counsel, at the reasonable expense of the Indemnitor, and within the indemnification limitations herein, if
representation of all parties by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing
interests between the parties in such proceeding. Failure of the Indemnitees to give prompt notice or to keep it informed, as provided
herein, shall not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is actually
and materially prejudiced by such failure. The Indemnitor shall not be liable nor shall it be required to indemnify or hold harmless
the Indemnitee in connection with any settlement effected without its consent in writing, which shall not be unreasonably withheld
or delayed.

 

(f) Sole
Remedy. The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall be the exclusive
remedy available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision does not limit
the right to seek specific performance, a restraining order or injunctive relief with respect to any provision of this Agreement.

 

11. Miscellaneous.

 

11.1 Survival
of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers
contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and each Closing and
shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers
or the Company.

 

    22

     

    

 

11.2 Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors
and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of
this Agreement, except as expressly provided in this Agreement.

 

11.3 Governing
Law. This Agreement shall be governed by the internal law of the State of Israel, without regard to conflict of law principles
that would result in the application of any law other than the law of the State of Israel.

 

11.4 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

11.5 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

11.6 Notices.

 

(a) General.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic
mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their address as set forth on the signature page or in the preamble to this Agreement, or to such e-mail address or address as
subsequently modified by written notice given in accordance with this Section ‎11.6.

 

11.7 No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission
in connection with this transaction. The Companies agrees to indemnify and hold harmless Purchaser from any liability for any commission
or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses
of defending against such liability or asserted liability) for which the Companies or any of its officers, employees or representatives
is responsible.

 

11.8 Fees
and Expenses. Each party to this Agreement shall bear the cost of their own respective legal fees and expenses.

 

11.9 Attorneys’
Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the
Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements
in addition to any other relief to which such party may be entitled.

 

11.10 Amendments
and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Companies,
Stockholders and Purchaser. Any amendment or waiver effected in accordance with this Section ‎11.10 shall be binding
upon the Purchaser and each transferee of the Primary Shares or Secondary Shares, each future holder of all such securities, the
Stockholders and the Companies.

 

    23

     

    

 

11.11 Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

11.12 Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

11.13 Entire
Agreement. This Agreement (including the Exhibits hereto), the Restated Certificates, Restated Bylaws and the other Transaction
Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof,
and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.

 

11.14 Corporate
Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER
OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION
THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE QUALIFICATION BY SECTION 25100,
25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON
THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.

 

11.15 Termination
of Closing Obligations. Purchaser shall have the right to terminate its obligations to complete the Closing if prior to the
occurrence thereof, any of the following occurs:

 

(a) the
either of the Companies consummates a Deemed Liquidation Event (as defined in the Restated Certificate);

 

(b) the
closing of an initial public offering of either of the Companies, in which case the Purchaser may terminate their obligations hereunder
immediately prior to, or contingent upon, such closing; or

 

(c) either
of the Companies (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any proceedings under the United States
Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting
the rights of creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take
advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency
petition filed against it, or (v) becomes subject to any involuntary proceedings under the United States Bankruptcy Code or any
other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors
generally, when proceeding is not dismissed within thirty (30) days of filing, or have an order for relief entered against it in
any proceedings under the United States Bankruptcy Code.

 

11.16 Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the competent courts of the
State of Israel and to the jurisdiction of Tel-Aviv courts for the purpose of any suit, action or other proceeding arising out
of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this
Agreement except in the state courts of Tel-Aviv, and (c) hereby waive, and agree not to assert, by way of motion, as a defense,
or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an
inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof
may not be enforced in or by such court.

 

[Signature Page
Follows]

 

    24

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	SMART REPAIR PRO, INC.:
	 	 
	 	By:	/s/ Julia Gerasimova
	 	Name:  	Julia Gerasimova
	 	Title:	Owner
	 	 	 
	 	PUREX, INC.:
	 	 
	 	By:	/s/ Galit Mccord
	 	Name:	Galit Mccord
	 	Title:	Owner

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	PURCHASER:
	 	 
	 	MEDIGUS LTD.
	 	 
	 	By:	/s/ Eli Yoresh
	 	Name:  	Eli Yoresh
	 	Title:	Chairman

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

	 	STOCKLHOLDERS:
	 	 
	 	JULIA GERASIMOVA
	 	 
	 	/s/ Julia Gerasimova
	 	 
	 	GALIT MCCORD
	 	 
	 	/s/ Galit Mccord
	 	 
	 	SOLY HACMON
	 	 
	 	/s/ Soly Hacmon
	 	 
	 	MANAGER:
	 	 
	 	VICKY HACMON
	 	 
	 	/s/ Vicky Hacmon

 

     

     

    

 

EXHIBITS
AND SCHEDULES

 

	Schedule 1	SCHEDULE OF STOCKHOLDERS
	Exhibit A	DISCLOSURE SCHEDULE

 

     

     

    

 

SCHEDULE 1

 

Schedule of
Stockholders

 

[***]

 

     

     

    

 

EXHIBIT A

 

Disclosure Schedule

 

[***]Exhibit 10.5

 

SHARE
PURCHASE AGREEMENT

 

THIS SHARE PURCHASE
AGREEMENT is made as of October 14, 2020, by and between Eventer Technologies Ltd., an Israeli company (the “Company”)
and Medigus Ltd. (the “Investor”).

 

WHEREAS, the Board
of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to
raise capital by means of issuance of the Company’s Ordinary Shares, nominal value NIS 0.1 per share (the “Ordinary
Shares”) to the Investor, at a purchase price of US$2.305777 per each Ordinary Share (the “Ordinary Share PPS”);
and

 

WHEREAS, the Investor
desires to purchase and the Company desires to issue and sell to the Investor the Ordinary Shares pursuant to the terms and conditions
more fully set forth in this Agreement.

 

NOW, THEREFORE, THE
PARTIES HEREBY AGREE AS FOLLOWS:

 

1. PURCHASE AND SALE
OF PURCHASED SHARES.

 

1.1 Sale and Issuance
of Shares. Subject to the satisfaction of the closing conditions set forth in Section ‎5 hereof, at the Closing (as defined
below), the Company shall issue and sell to the Investor, and the Investor shall purchase, from the Company, according to the allocation
set forth in Exhibit A attached hereto, for an aggregate purchase price of US$750,000 (the “Purchase Price”),
an aggregate of 325,270 Ordinary Shares (the “Purchased Shares”) at the Ordinary Share PPS, representing 50.01%
of the Company’s share capital on a Fully Diluted Basis (the “Investor Closing Holdings”) reflecting a
pre-money valuation on a Fully-Diluted Basis (as defined below) of US$749,600.

 

The capitalization
table of the Company, reflecting the issued and outstanding share capital of the Company on a Fully Diluted Basis, immediately
prior to Closing and immediately following the Closing, assuming the investment of the Purchase Price, is attached hereto as Exhibit
B (the “Capitalization Table”).

 

In this Agreement,
“Fully-Diluted Basis” shall mean all issued and outstanding shares of the Company, including but not limited
to (i) all Ordinary Shares; (ii) all securities convertible or exercisable into shares (being deemed so converted); (iii) all convertible
investments, financings or loans (being deemed so converted); (iv) all options, warrants and other rights to acquire shares or
other securities exercisable for shares (being deemed allocated and so exercised) (excluding the Allocated Option and Anti-Dilution
Protection Shares); and (v) any adjustments of the number of issued shares triggered by or in connection with the transaction contemplated
by this Agreement (if any), including anti-dilution adjustment.

 

Notwithstanding the
aforesaid, with respect to the (a) reservation of 74,100 options to purchase Ordinary Shares for options and other equity awards
promised to such persons and entities listed in Schedule 1.1 (the “Allocated Options”), and (b) an additional
reservation of 8,410 Ordinary Shares which may be issued upon issuance of certain of the Allocated Options, all as described in
Schedule 1.1 (the “Anti-Dilution Protection Shares”), if any shares shall be issued following the exercise of
any Allocated Options and if any Anti-Dilution Protection Shares shall be issued, then the Company shall issue to the Investor,
for no additional consideration and with no other action required on the part of the Company or the Investor, such number of Ordinary
Shares that would result in no dilution of the Investor’s proportionate holding in the Company due to any such issuances
(i.e. the Investor’s holding shall not fall below the Investor Closing Holdings, except to the extent such dilution results
from further issuances approved in accordance with the Restated Articles) (the “Adjustment Shares”) and the
Company shall deliver to the Investor a share certificate representing such Adjustment Shares, register the Adjustment Shares in
the Company’s Shareholders Register and file all required notices with the Israeli Registrar of Companies. The Adjustment
Shares shall be deemed, for all purposes, as “Purchased Shares” that have been issued as of the Closing.

 

     

     

    

  

1.2 Closing.
The consummation of the transactions contemplated hereby, including the purchase and sale of the Purchased Shares (the “Closing”)
shall take place remotely via the exchange of documents and signatures, at such time and place as the Company and Investor mutually
agree upon (such designated time and place, the “Closing Date”). The Closing shall be subject to the conditions
of Section ‎5 below, which conditions shall be deemed to take place simultaneously and no transaction described in such sections
shall be deemed to have been completed or any document delivered until all such transactions have been completed and all such required
documents delivered.

 

1.3 Restated Articles.
The Company shall adopt on or before the Closing the Amended and Restated Articles of Association in the form attached hereto as
Exhibit C (the “Restated Articles”). The Purchased Shares shall have and confer upon the holders
thereof the rights, preferences, privileges and restrictions set forth in the Restated Articles, as may be amended from time to
time in accordance with their terms.

 

1.4 Second Tranche
Closing.

 

(a) If following the
Closing, the Company shall determine that the EBIDTA set forth in Schedule 1.4 has been achieved, in whole or in part (in
which case, the rate of achievement shall be stated) (the “Milestone Conditions”), the Company shall deliver
a written notice (a “Second Tranche Notification”) to the Investor that a closing of the purchase and sale of
1 additional Ordinary Share (the “Second Tranche Closing Share”) (the “Second Tranche Closing”)
is to take place pursuant to this Subsection 1.4. The Second Tranche Notification shall include the proposed date for the
Second Tranche Closing, which date shall be no earlier than fourteen (14) days after the date of the Second Tranche Notification.
Subject to the terms and conditions of this Agreement and at the Second Tranche Closing, the Company shall sell and issue to the
Investor and the Investor shall purchase at the Second Tranche Closing the Second Tranche Closing Share against payment of US$250,000
or a proportionate portion thereof, in accordance with the level of achievement of the Milestone Conditions (the “Second
Tranche Amount”), by wire transfer to a bank account designated by the Company. Notwithstanding the foregoing, in lieu
of the issuance of the Second Tranche Closing, the Parties may mutually agree to apply an additional premium on account of the
Purchased Shares. In case of issuance of the Second Tranche Closing Share, all shares held by the Investor shall be deemed to have
effective price per share equal to the total amount of the Purchase Price and the Second Tranche Amount divided by the total number
of shares purchased by the Investor.

 

The initial consideration
and determination whether or not the Milestone Conditions shall have been achieved shall be made by the directors of the Company
excluding the Medigus Directors (as defined in the Restated Articles). Upon receipt of the Second Tranche Notification, the Investor
may ask for any information and clarifications it deems necessary to determine whether the Milestone Conditions have been met,
and it may also respond with an objection to the Second Tranche Notification based on its position that the Milestone Conditions
have not been achieved. In such case of disagreement, the parties may refer the matter to an arbitrator to be mutually agreed upon,
and in case of disagreement, the matter would be dealt with pursuant to the provisions of Section 8.5 of this Agreement. The Investor
shall not be required to pay any portion of the Second Tranche Amount until a non-appealable decision has been made. In all such
actions, the Medigus Directors shall not be involved in their capacities as directors, in any actions taken by the Company with
respect to the Second Tranche Closing.

 

(b) The Investor’s
obligation to transfer the Second Tranche Amount and purchase the Second Tranche Closing Share at the Second Tranche Closing may
be satisfied by any person or entity that is a Permited Transferee of the Investor (as such term is defined in the Restated Articles)
(the “Additional Investor”), subject to compliance with the provisions of Section 20.1.1 of the Restated Articles,
applied as if this is a Transfer; provided, that the Investor alone shall remain the party to this Agreement, such as for purposes
of the Share Exchange Option Agreement, the Information Rights Agreement, etc.; provided however that the Additional Investor shall
provide a letter of confirmation regarding the provisions of Section 3 of this Agreement.

 

    2

     

    

  

(c) For any and all
purposes under this Agreement and any other Transaction Documents, the date of issuance of the Second Tranche Closing Share shall
be deemed to be the date of Closing, specifically for purposes of the provisions of Section 7 of this Agreement.

 

(d) Notwithstanding
the foregoing, the obligations of the Investor under this Subsection 1.4 shall terminate and be of no further force or effect upon
the earlier of (i) December 31, 2023, or (ii) immediately prior to the consummation of a Deemed Liquidation (as defined
in the Restated Articles).

 

1.5 Closing Deliverables.

 

(a) At the Closing,
the Company shall deliver to the Investor:

 

(i) True and correct
copies of written resolutions, or minutes of a meeting, of the Board, approving and adopting in all respects the execution, delivery
and performance by the Company of this Agreement and the transactions contemplated hereby, including, among others, (i) authorizing
the issuance and sale of the Purchased Shares against payment of the purchase price therefor; (ii) the approval of the execution,
delivery and performance by the Company of all agreements contemplated herein to which the Company is party and any agreements,
instruments or documents ancillary thereto; (iii) reservation of 74,100 Ordinary Shares for issuance to directors, officers, consultants
and employees of the Company or its subsidiaries; (iv) reservation of 8,410 Ordinary Shares for issuance pursuant to the provisions
of Schedule 1.1; and (iv) the adoption of new signatory rights; all in the form attached hereto as Schedule ‎1.5(a)(i);

 

(ii) True and correct
copies of written resolutions, or minutes of meeting, of the Company’s shareholders approving and adopting in all respects
the execution, delivery and performance by the Company of this Agreement and the transactions contemplated hereby, including, among
others, (i) the adoption of the Restated Articles as an amendment and restatement of the existing Articles of Association of the
Company as in effect prior to the Closing; and (ii) the approval of the execution, delivery and performance by the Company of all
agreements contemplated herein to which the Company is party and any agreements, instruments or documents ancillary thereto; all
in the form attached hereto as Schedule ‎1.5(a)(ii);

 

(iii) A copy of the
Restated Articles;

 

(iv) The Share Exchange
Option Agreement, in the form attached hereto as Exhibit D (the “Share Exchange Option Agreement”),
duly executed by the Company and certain of its shareholders;

 

(v) A duly executed
share certificate representing the Purchased Shares issued to the Investor at the Closing in the name of the Investor, in the form
attached hereto as Schedule ‎1.5(a)(v);

 

(vi) A copy of the
register of shareholders of the Company (the “Shareholders Register”), certified by an executive officer of
the Company and prepared in accordance with Section 130 of the Companies Law, 5759–1999, as amended (the “Companies
Law”), in which the Purchased Shares issued at the Closing are registered in the name of the Investor, in the form attached
hereto as Schedule ‎1.5(a)(vi);

 

    3

     

    

 

(vii) Duly completed
notices to the Israeli Registrar of Companies, in the forms attached hereto as Schedule 1.5‎(vii), ready
for immediate filing, as are required for all matters arising from this Agreement and the transactions contemplated hereby (including,
of the issuance of the Purchased Shares at the Closing, the adoption of the Restated Articles and the changes to the composition
of the Board);

 

(viii) True and correct
copies of all waivers of preemptive rights (if the period for exercise of such right has not lapsed in accordance with its terms)
by all holders of such rights, with respect to this Agreement and the transactions contemplated hereby;

 

(ix) Deleted

 

(x) Director indemnification
agreements with the members of the Board, including the director(s) appointed by the Investor (the “Indemnification Agreement”),
duly approved by the Board and shareholders and executed by the Company, in the form attached hereto as Schedule ‎1.5(a)(x);

 

(xi) Information
Rights Agreement, dated as of the Closing, duly executed by the Company, in the form attached hereto as Schedule 1.5(a)(xi);

 

(xii) a certificate
duly executed by an executive officer of the Company as of the Closing stating that the conditions specified in Section ‎5
have been satisfied, in the form attached hereto as Schedule ‎1.5(a)(xii); and

 

(xiii) an executed
copy of the Revolving Promissory Note, in the form attached hereto as Schedule 1.5(a)(xiii) (the “Revolving Promissory
Note”).

 

(b) At the Closing,
the Investor shall deliver to the Company:

 

(i) The Share Exchange
Option Agreement;

 

(ii) Any identification
documents required for the purpose of making the filings required under Section ‎1.5(a)(vii);

 

(iii) The Indemnification
Agreement, duly executed by the director appointed by the Investor; and

 

(iv) The Revolving
Promissory Note, duly executed by the Investor.

 

1.6 Purchase Price.
At the Closing, the Investor shall transfer to the Company the Purchase Price to be invested at the Closing by wire transfer of
immediately available funds according to the Company’s wire instructions (details of which will be provided by the Company
in writing prior to the Closing).

 

1.7 Adjustment
of Shenhav-Eventer LP’s Holdings. Immediately prior to the Closing, Shenhav-Eventer LP shall be issued 14,500 additional
Ordinary Shares of the Company, as compensation for their dilution by the purchase of shares by the Investor.

 

2. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

The Company hereby
represents and warrants to the Investor that, except as set forth on the Disclosure Schedule delivered to the Company on the date
hereof (the “Disclosure Schedule”), which exceptions shall be deemed to be part of the representations and warranties
made hereunder, the following representations are true, correct and complete as of the date hereof and as of the Closing (as if
made on the Closing Date); except, in each case, as to such representations and warranties that address matters as of a particular
date, which are true, correct and complete only as of such date. The Disclosure Schedule is arranged in sections and subsections
corresponding to the numbered and lettered sections and subsections contained in this Section ‎2, and the information set forth
in any one in any section or subsection of the Disclosure Schedule applies to and qualifies (a) the representation and warranty
set forth in this Agreement to which it corresponds, and (b) whether or not an explicit reference or cross-reference is made, each
other representation and warranty set forth in this Agreement for which it is reasonably apparent on its face that such information
is relevant to such other section.

 

    4

     

    

  

“Material
Adverse Effect” means a material and adverse affect on the assets, properties, conditions (financial or otherwise), operating
results or business of the Company, as currently conducted and as currently proposed to be conducted.

 

2.1 Organization.
The Company is a company duly organized and validly existing under the laws of the State of Israel, is not a “breaching company”
(within the meaning of Section 362.A of the Israeli Companies Law) and has all requisite corporate power and authority to carry
on its business as currently conducted and as currently proposed to be conducted.

 

2.2 Capitalization.

 

(a) The authorized
share capital of the Company is or will be on or immediately prior to the Closing (but following the adoption of the Restated Articles),
as set forth in the Restated Articles, and such number of shares of each class as set forth in the Capitalization Table are or
shall be (as of the Closing) issued and outstanding.

 

(b) The outstanding
securities of the Company, on a Fully-Diluted Basis, are owned by and registered in the names of such security holders, and in
such numbers as specified in the Capitalization Table and in Section ‎2.2‎(b) of the Disclosure Schedule.

 

(c) The Board has
reserved 74,100 Ordinary Shares prior to the Closing for issuance of, and grant of options or other equity awards exercisable into,
Ordinary Shares of the Company to directors, officers, employees, consultants and service providers of the Company or its subsidiaries
under the Company’s 2017 Employee Share Option Plan or under other grant agreements and schemes (the “Plan”
and the “ESOP Pool”, respectively), all of which have been allocated and/or promised. The Company has furnished
to the Investor complete and accurate copies of the Plan and forms of agreements adopted thereunder. Section ‎2.2‎(c)
of the Disclosure Schedule sets forth for each outstanding or promised option or equity award: (i) the name of the holder thereof;
(ii) the exercise price, (iii) the vesting commencement date and vesting schedule (and any acceleration terms, if any); (iii) whether
each such option or award was granted and is subject to tax pursuant to Section 3(i) or Section 102 of the Israeli Income Tax Ordinance
[New Version], 1961 (and specifying the subsection of Section 102) or tax regimes of other jurisdictions.

 

(d) The issued and
outstanding shares of the Company were duly and validly authorized and issued, fully paid and non-assessable, and offered and issued
in compliance with the provisions of the Company’s Articles of Association as in effect at the time of each such issuance
and in compliance with all applicable corporate and securities laws. None of the issued and outstanding shares of the Company was
offered or sold in such a manner as to make the offer, issuance or sale of such shares not exempted from registration requirements
under applicable securities law.

 

(e) Except for the
preemptive rights and bring-along provisions under applicable law or in the Restated Articles, there are no outstanding share capital,
options, warrants, rights (including conversion, preemptive rights, rights of first refusal or similar rights) or agreements for
the purchase from the Company of any of its share capital, or any securities convertible into or exchangeable for shares of the
Company (whether now or hereinafter authorized or issued), other than as set forth in the Capitalization Table, or that could require
the Company or a shareholder of the Company to issue, sell, transfer or otherwise cause to be outstanding any of the Company’s
share capital or securities convertible or exercisable into shares thereof.

 

    5

     

    

  

(f) No option, security
or other equity award convertible or exercisable into shares of the Company contains a provision for acceleration of vesting (or
lapse of a repurchase right) or other changes in the vesting provisions or other terms of such option, security or other equity
award upon the occurrence of any event or combination of events, including without limitation in the case where the Plan is not
assumed in an acquisition. No share, option, security or other equity award convertible or exercisable into shares of the Company
is subject to repurchase or redemption (contingent or otherwise) by the Company, its subsidiaries or its shareholders, and neither
the Company nor any subsidiary or shareholder have repurchased or redeemed any of the Company’s shares, options, security
or other equity awards. The Company has never adjusted or amended the exercise price or any other terms of any options previously
awarded, whether through amendment, cancellation, replacement grant, repricing, or any other means.

 

(g) The Company has
not granted or agreed to grant registration rights and is not under any contractual obligation to register under the U.S. Securities
Act of 1933 (together with the rules and regulations promulgated thereunder, all as amended, the “Securities Act”),
any of its currently outstanding securities, securities that may hereafter be issued upon conversion thereof, or shares or other
securities it may hereafter issue or grant.

 

(h) The Company has
not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its share
capital.

 

2.3 Authorization.
All corporate action on the part of the Company, its directors and shareholders, necessary for the authorization, execution and
delivery of this Agreement, and the other agreements, instruments or documents entered into in connection with this Agreement and
to which the Company is a party (collectively, the “Transaction Documents”) and for the performance of all obligations
of the Company under the Transaction Documents in accordance with their terms has been taken or will be taken prior to the Closing.
The Transaction Documents, when executed and delivered by the Company, and assuming the due authorization, execution and delivery
by the other parties hereto and thereto, constitute valid and binding obligations of the Company, enforceable against the Company
in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights
generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies.

 

2.4 Valid Issuance
of Shares. The Purchased Shares that may be issued to the Investor hereunder, when issued, sold and delivered in accordance
with the terms of this Agreement for the consideration expressed herein, shall be duly and validly issued, fully paid, and non-assessable,
issued in compliance with all applicable state securities laws, and free and clear of liens, pledges, charges, encumbrances or
other restrictions on transfer of any kind (including, without limitation, preemptive rights), other than restrictions on transfer
under this Agreement, the Company’s Articles of Association (or, upon Closing, the Restated Articles) and under applicable
securities laws and other than liens or encumbrances created by or imposed on each Investor as to itself. The offer, sale and issuance
of the Purchased Shares to be issued pursuant to this Agreement constitute transactions exempted from the registration requirements
of Section 15 of the Securities Act and the Israeli Securities Law, 1968, as amended. The rights, privileges and preferences
of the Purchased Shares are as stated in the Restated Articles, as may be amended from time to time in accordance with its terms.

 

    6

     

    

 

2.5 No Conflict;
Consents. The execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated
by the Transaction Documents do not and will not (a) result in any conflict with, or a breach or violation, with or without the
passage of time and giving of notice, of any of the terms, conditions or provisions of, or give rise to rights to others (including
rights of termination, cancellation or acceleration) under: (i) the Company’s Articles of Association, as in affect prior
to the Closing; (ii) any judgment, injunction, order, writ, decree or ruling of any court or governmental authority, domestic or
foreign, to which the Company is subject; (iii) any material contract or agreement, lease, license or commitment to which the Company
is a party or by which it is bound; or (iv) any applicable law; (b) result in the creation of any lien, charge or encumbrance upon
any asset of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable
to the Company; or (c) require the consent, approval or authorization of, registration, qualification or filing with, or notice
to any person or any federal, state, local or foreign governmental authority or regulatory authority or agency, on the part of
the Company, which has not heretofore been obtained or made or will be obtained or made prior to Closing, except the filing of
the Restated Articles and the other required notices specified in Sections ‎1.4 with the Israeli Registrar of Companies, each
of which shall be made as soon as practicable following the Closing.

 

2.6 Directors;
Officers. The directors, observers and officers of the Company are listed on Section ‎2.6 of the Disclosure Schedule. The
Company has no agreement, obligation or commitment with respect to the election of any individual to its Board or to the right
to nominate an observer to the Board, and, to the Company’s knowledge, there is no such agreement among the Company’s
shareholders, except as stated in the Restated Articles. All agreements, commitments and understandings of the Company, whether
written or oral, with respect to any compensation to be provided to any of the Company’s directors, observers or officers
have been fully disclosed in writing to the Investor prior to the Closing.

 

2.7 Subsidiaries.
The Company does not own or control, directly or indirectly, any interest or any other right in any other corporation, association,
or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement.

 

2.8 Compliance
with Laws and Other Instruments. The Company is, and has been, in compliance, in all material respects, with all applicable
laws (including export, import and other trade compliance laws). The Company has not received any written notice of or been charged
with the violation of any law and, to Company’s knowledge, there is no threatened action or proceeding against the Company
under any of such laws. The Company is not in violation of or default under (i) any provisions of its Articles of Association as
in affect prior to the Closing, (ii) any order, writ, injunction, decree or judgment of any court or any governmental department,
commission or agency, domestic or foreign, to which it is subject or by which it is bound. The Company has obtained all franchises,
permits, licenses, consents and any similar authorizations that are material to its business as currently conducted and as currently
proposed to be conducted under applicable law, and is in compliance, in all material respects, with such franchises, permits, licenses,
consents and similar authorizations. None of the Company’s products, intellectual property or operations is subject to any
restriction or limitation or requires a license or registration under applicable laws relating to marketing, export or import controls.
Without limiting the generality of the foregoing, the Company has not and is not using or developing, or otherwise engaged in,
encryption technology or other technology whose development, commercialization or export is restricted, and the conduct of the
business as currently conducted and as currently proposed to be conducted does not require obtaining a license from the Israeli
Ministry of Defense or an authorized body thereof pursuant to Section 2(a) of the Control of Products and Services Declaration
(Engagement in Encryption), 1974, or from the Israeli Ministry of Economy pursuant to the Law of Regulation of Security Exports,
2007.

 

    7

     

    

 

2.9 Financial
Statements; No Undisclosed Liabilities.

  

(a) The Company has
made available to each Investor its audited financial statements for the fiscal year ended December 31, 2019, and its unaudited
financial statements (including balance sheet, profit and loss and income statement and statement of cash flows, excluding notes
thereto) as of June 30, 2020 (collectively, the “Financial Statements”). The Financial Statements have been
prepared in accordance with the Israeli generally accepted accounting principles (“GAAP”) applied on a consistent
basis throughout the periods indicated, except that the unaudited Financial Statements may not contain all footnotes required by
GAAP. The Financial Statements fairly present in all material respects the financial condition and operating results of the Company
(if applicable, on a consolidated basis), as of the dates, and for the periods, indicated therein, subject in the case of the unaudited
Financial Statements to normal year-end audit adjustments that individually and in the aggregate are not material.

 

(b) The Company has
no liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business
subsequent to December 31, 2019, which, individually and in the aggregate, do not exceed US$10,000; (ii) obligations under contracts
and commitments incurred in the ordinary course of business; and (iii) liabilities and obligations listed in Section 2.9 of the
Disclosure Schedule.

 

(c) The Company is
not a guarantor or indemnitor of any debt or obligation of another, nor has the Company given any loan, security or otherwise agreed
to become liable for any obligation of any person. No person has given any guarantee of, or security for, any obligation of the
Company. The Company did not extend any loans or advances to any person, other than advances for expenses to its employees in the
ordinary course of business.

 

(d) The Company maintains
a standard system of accounting established and administered in accordance with GAAP.

 

2.10 Absence of
Certain Changes. Since December 31, 2019, except as set out in Section 2.9 and except as set out in Section 2.10 of the Disclosure
Schedule, there has not been:

 

(a) any change in
the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial Statements,
except for changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect;

 

(b) any damage, destruction
or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 

(c) any waiver or
compromise by the Company of a valuable right or of a debt owed to it that, in each case, is material to the assets, properties,
conditions (financial or otherwise), operating results or business of the Company, as currently conducted and as currently proposed
to be conducted;

 

(d) any satisfaction
or discharge of any lien, claim or encumbrance, or payment of any obligation by the Company, in each case except in the ordinary
course of business and the satisfaction, discharge or payment of which would not be material to the assets, properties, conditions
(financial or otherwise), operating results or business of the Company, as currently conducted and as currently proposed to be
conducted;

 

(e) any resignation
or termination of employment of any officer or key employee of the Company;

 

(f) any mortgage,
pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or
assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially
impair the Company’s ownership or use of such property or assets;

 

(g) any loans or guarantees
made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate families,
other than travel advances and other advances made in the ordinary course of its business;

 

    8

     

    

  

(h) any declaration,
setting aside, payment or other distribution in respect of any of the Company’s share capital, or any direct or indirect
redemption, purchase or other acquisition of any of such share capital by the Company;

 

(i) any sale, assignment,
lease of or transfer of any of the Company’s assets (whether tangible or intangible), except in the ordinary course of business;

 

(j) receipt of any
notice that there has been a loss of, or material order cancellation by, any major customer of the Company;

 

(k) to the Company’s
knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s industry
generally, that could reasonably be expected to result in a Material Adverse Effect; or

 

(l) any arrangement
or commitment by the Company to do any of the things described in this Section ‎2.10.

 

2.11 Assets and
Properties. The Company has good and marketable title to all of the tangible or
personal properties and assets owned by the Company, which are material to the business of the Company as currently conducted
and as currently proposed to be conducted, and such properties and assets are free and clear of all mortgages, deeds of trust,
liens, pledges, charges, security interests, conditional sale agreement, loans and encumbrances, except for statutory liens for
the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business
and do not materially impair the Company’s ownership or use of such property or assets. With respect to the tangible
property and assets it leases, the Company is in compliance in all material respects with such leases and, to its knowledge, holds
a valid leasehold or license interest free of any liens, pledges, charges, security interest, claims or encumbrances, other than
those of the lessors of such property or assets. The Company does not own any real property.

 

2.13 Intellectual
Property. Terms used but not otherwise defined in this Section ‎2.12 shall
have the meaning set forth in Section ‎(h) below.

 

(a) The Company owns
or has the right to use, or can acquire on commercially reasonable terms, sufficient legal rights to all Company Intellectual Property
without any known conflict with, or infringement of, the rights of others, including without limitation the past and present employees
and consultants and employers of the past and present employees and consultants of the Company, free and clear of all liens, charges,
claims and restrictions. To the Company’s knowledge, no product or service marketed, sold or rendered (or proposed to be
marketed, sold or rendered) by the Company violates or will violate any license or infringes or will infringe any intellectual
property rights of any other person. Other than with respect to commercially available software products under standard end-user
object code license agreements or agreements providing for confidentiality of information entered into in the ordinary course of
business, the Company is not bound by or a party to any options, licenses or agreements of any kind with respect to the patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any
other person. Other than non-exclusive license agreements in the Company’s standard form of license agreement, which form
was provided to the Investor, and other than with respect to commercially available software products under standard end-user object
code license agreements or agreements providing for confidentiality of information entered into in the ordinary course of business,
there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating
to the Company Intellectual Property. The Company is not obligated or under any liability whatsoever (contingent or otherwise)
to make any payments by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any patent, trademark,
service mark, trade name, copyright or other intangible asset, with respect to the use thereof or in connection with the conduct
of its business as currently conducted and as currently proposed to be conducted. The Company has not received and is not aware
of any communications alleging that the Company has violated or, by conducting Company’s business, would violate any of the
patents, trademarks, service marks, trade names, copyrights, trade secrets, mask works or other proprietary rights or processes
of any other person. To the Company’s knowledge, no person has violated or is violating the Company Intellectual Property
owned by the Company. The Company has obtained and possesses valid licenses to use all of the software programs present on the
computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees
for their use in connection with the Company’s business.

 

    9

     

    

  

(b) Section ‎2.13
of the Disclosure Schedule is a complete list of all (i) patents, trademarks, service marks, trade names, copyrights, domain name,
registration with respect to any of the Company Intellectual Property and any applications for and under any of the foregoing;
and (ii) unregistered trademark.

 

(c) All of the Company’s
employees and consultants, past and present, who were or are engaged in the development, invention, discovery, programming or design
of any Company Intellectual Property, have entered into written agreements with the Company assigning to the Company all rights,
title and interests in Company Intellectual Property developed, invented, programmed, designed, conceived or reduced to practice
(either alone or jointly with others) in the course of their employment or engagement, as the case may be, or that relate to the
Company’s business as currently conducted and as currently proposed to be conducted, and explicitly waiving all non-assignable
rights (including moral rights) and rights to receive royalties or compensation in connection therewith (including, without limitation,
under Section 134 of the Israeli Patent Law, 1967). Any and all Company Intellectual Property which has been, is currently being
or will be developed by any employee or consultant of the Company is and shall be the sole property of the Company. The Company
has taken all required security measures to protect the secrecy, confidentiality and value of all the Company Intellectual Property,
which measures are reasonable and customary in the industry in which the Company operates and, to the Company’s knowledge,
there has been no breach of security of the Company’s systems involving any such information. To the Company’s knowledge,
it will not be necessary to use any of the developments, ideas, inventions, trade secrets, proprietary information or other intellectual
property of any of its employees or consultants made prior to their employment or engagement by the Company.

 

(d) No funding or
grants from, or facilities of, a governmental body or institution, university, college or other academic or educational institution
or research center, or organization whose primary purpose is to create or foster the creation of Open Source Software (as defined
below) (or any affiliate of any of the foregoing), was used by the Company or on its behalf, or by any of its founders prior to
the incorporation of the Company, in the development of the Company Intellectual Property. Other than as set forth in Section
‎2.13‎(d) of the Disclosure Schedule, to the knowledge of the Company, no current or former employee, consultant
or independent contractor of the Company, who is or was involved in, or who is contributing or contributed to the creation or development
of any Company Intellectual Property is or has performed services for or otherwise is or was under restrictions resulting from
his or her relations with any government, university, college or other academic or educational institution or research center,
or organization whose primary purpose is to create or foster the creation of Open Source during the time such employee, consultant
or independent contractor is or was so involved in, or contributing to the creation or development of any Company Intellectual
Property.

 

    10

     

    

 

(e) All of the rights,
title and interests in the Company Intellectual Property that was developed, invented, programmed, designed, conceived or reduced
to practice by Julien Azoulay (the “Founder”) (either alone or jointly with others) prior to, upon or with a
view of the incorporation of the Company, if any (“Founder IP”) was duly, fully and irrevocably assigned by
the Founder to the Company upon or in connection with the incorporation of the Company, free and clear of any liens, charges, claims
and restrictions, and, to the extent already required, all declarations and documents required by the various patent offices in
the countries in which the Company Intellectual Property was registered in order to register such assignments have been duly executed,
submitted, approved and registered. The Founder is the sole inventor and developer of the Founder IP (including the inventions,
methods and devices described and claimed in the patents which are part of such Founders IP, if any) without any contribution,
assistance, participation or alleged rights of any third party. Neither the Founder nor, to the Company’s knowledge, any
other person has any further interest in or rights to any of the Founder IP. During the period in which the Founder was developing
the Founder IP, the Founder was not employed or engaged by any third party. The Founder is not and was never employed by, engaged
with or a staff member of any governmental body or institution, university, college or other academic or educational institution
or research center, or organization whose primary purpose is to create or foster the creation of Open Source Software.

 

(f) All use and distribution
of the Company’s products and services and any Open Source Software by or on behalf of the Company is in compliance, in all
material respects, with Open Source Software licenses applicable thereto, including without limitation all copyright notice and
attribution requirements. The Company has not embedded, incorporated, bundled, linked to, used or distributed any Open Source Software
in connection with any of its products or services that are available to any third party or otherwise in development in any manner
that would restrict the ability of the Company to protect its proprietary interests in any such product or service or in any manner
that requires, or purports to require (i) any Company’s products, services or any portion thereof, or any other Company Intellectual
Property (other than the Open Source Software itself) to be disclosed or distributed in source code form or to be licensed for
the purpose of making derivative works; (ii) any restriction on the consideration to be charged for the distribution of any Company’s
products, services or any portion thereof, or any other Company Intellectual Property; (3) the creation of any obligation for the
Company with respect to Company’s products, services or any portion thereof, or any other Company Intellectual Property,
or the grant to any third party of any rights or immunities under Company Intellectual Property owned by the Company; or (4) any
other limitation, restriction or condition on the right of the Company with respect to its use, distribution or rendering of any
Company’s products, services or any portion thereof, or any other Company Intellectual Property.

 

(g) No source code
of any of the Company’s proprietary software has been licensed (as such) or otherwise provided or disclosed to another person
or entity, and the Company does not have any duty or obligation (whether present, contingent, or otherwise) to license (as such)
or otherwise provide the source code for any of the Company’s proprietary software to any person.

 

(h) Definitions.
The following terms used in this Agreement shall have the meanings set forth below:

 

“Company
Intellectual Property” means all patents, patent applications, trademarks, trademark applications, service marks, service
mark applications, trade names, copyrights, trade secrets, know-how, inventions, designs, works of authorship, computer programs
and technical data, domain names, mask works, information and proprietary rights and processes, similar or other intellectual property
rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses and rights in, to and under
any of the foregoing, in any and all such cases that are owned or used by and, to the Company’s knowledge, as are necessary
for the Company in the conduct of the Company’s business as currently conducted and as currently proposed to be conducted.

 

“knowledge”,
including the phrase “to the Company’s knowledge” (or similar phrases), when used in this Section ‎2.13
(Intellectual Property) shall mean the actual knowledge of the Company, without conducting any patent search, freedom to
operate, infringement, or any similar search.

 

“Open Source
Software” shall mean all software or other material that is distributed as “free software”, “open source
software” or under a similar licensing or distribution terms (including but not limited to the GNU General Public License
(GPL), Affero GPL, GNU Lesser General Public License (LGPL), Library General Public License, Lesser General Public License, Mozilla
Public License (MPL), Eclipse Public License (EPL), Common Development and Distribution License, BSD licenses, the Artistic License
and the Apache License), Berkeley Software Distribution license, Open Source Initiative license, MIT, and/or Public Domain licenses,
freeware type licenses or other distribution model described by the Open Source Initiative at www.opensource.org).

 

    11

     

    

  

2.15 Data Privacy.
In connection with its collection, storage, transfer (including, any transfer across national borders) and/or use of any personally
identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or
other third parties (including, information that alone or in combination with other information can be used to specifically identify
a person or any financial services data collected or used by the Company) (collectively “Personal Information”),
in any manner (including, through internet websites or (if applicable) mobile applications owned, maintained or operated by the
Company (“Company Sites”), through any products or services provided to customers of the Company, or maintained
by third parties having authorized access to such information), the Company has not yet taken any specific actions and following
the Closing will conduct a thorough review of all actions required in order to ensure compliance, in all material respects, with
all applicable laws in all relevant jurisdictions. No action, claim, proceeding, compliant, inquiry, audit or investigation is
pending or, to the Company’s knowledge, threatened against the Company, the Founder or any of its officers, directors, or
employees (in their capacity as such) by any private party or any governmental authority, foreign or domestic, with respect to
Personal Information. There has been no loss, unauthorized access to or other misuse by or on behalf of the Company of such
Personal Information, and, to the knowledge of the Company, no third party misused any Personal Information collected by the Company.

 

2.16 Material
Agreements.

 

(a) Section 2.16‎(a)
of the Disclosure Schedule contains a true and complete list of all material contracts, agreements, instruments, transactions,
judgments, orders, writs or decrees to which the Company is a party or by which it is bound, including the following (each, a “Material
Agreement”), true and correct copies of which have been made available to the Investor:

 

(i) any obligations
(contingent or otherwise) of, or payments to, the Company in excess of US$ 10,000 individually or in the aggregate;

 

(ii) any license
of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company (other than non-exclusive licenses
from the Company entered into in the ordinary course of business, or commercially available software products under standard end-user
object code license agreements licensed to the Company);

 

(iii) any grant of
rights to manufacture, produce or assemble the Company’s products to any other person;

 

(iv) any agreement
granting any other person the right to market, distribute or resell (including as an OEM or value-added reseller) any of the Company’s
technology, products or services;

 

(v) any covenants,
restrictions or limitations on the Company’s right to do business (including, the Company’s exclusive right to develop,
manufacture, assemble, distribute, market or sell its products or services) or compete in any area, field or geography with any
person (including any exclusivity with respect to any geographic territory, any customer, or any product or service), or any agreement
providing any person a right of first notification, right of first offer, right of first refusal or exclusivity in case of a sale
(or offer to sell) the Company or any of its shares or assets or with respect to the provision of services or products to the Company;

 

(vi) any indemnification
by the Company with respect to infringements of proprietary rights (other than non-exclusive licenses from the Company entered
into in the ordinary course of business);

 

    12

     

    

  

(vii) any joint development
agreement, joint venture agreement, collaboration agreement, strategic alliance agreement or agreement involving the sharing of
profits, losses, costs or liabilities with any other person;

 

(viii) any lien,
charge, pledge or other encumbrance on the Company’s assets, properties or rights;

 

(ix) any agreement
for the sale, exchange or other disposition of any of the assets or rights of the Company to any person, or of any person by the
Company, other than the sale of inventory in the ordinary course of business;

 

(x) any agreement
which is otherwise material to the Company; or

 

(xi) any proposed
offer, arrangement or commitment by the Company to enter into or effect any of the foregoing agreements in this Section ‎2.15‎(a).

 

(b) The Material Agreements
are valid, binding and in full force and effect, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights
generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies. Neither the Company nor, to the Company’s knowledge, any other party thereto, is in breach of any Material Agreement.
No party to any Material Agreement has made a written claim to the Company to the effect that the Company has failed to perform
any material obligation thereunder, nor has any such party notified the Company of an intention to terminate, or not to renew,
any such contract or agreement.

 

2.17 Labor Matters.

 

(a) True, correct
and complete copies of all employment or consulting contracts, deferred compensation agreements, bonus, incentive, profit-sharing,
deferred compensation, pension or severance plans, and other like benefits (whether on retirement, death or termination or during
periods of sickness or disability), currently in force and effect for the benefit of any current or former officer, director, employee
or consultant of the Company (or for the benefit of the dependents of any such person), as well as a description of any policy,
practice, or custom currently in force and effect, have been made available to the Investor. The Company does not currently operate
any share or equity incentive plan for the benefit of any of its officers, directors, employees or contractors, other than the
Plan. Other than as required by applicable law, the Company has no agreement, policy, custom, practice, plan or program for the
payment of any form of severance or other payments in connection with the termination of employment services.

 

(b) Each officer and
key employee of the Company (other than directors, who are not employees of the Company) is currently devoting one hundred percent
(100%) of his or her business time to the conduct of the business of the Company, and the Company is not aware of any other officer
or key employee of the Company planning to work less than full-time at the Company in the near future.

 

(c) The Company has
no employment agreement or engagement with any officer, employee or consultant, which is not terminable by it at will without liability,
upon up to 30 days prior notice. No key employee of the Company has been dismissed or has given notice of termination of his/her
employment in the last 12 months period preceding the date of this Agreement, nor to the Company’s best knowledge, do any
of the officer or key employees of the Company have at present any intention to terminate his or her employment agreement.

 

    13

     

    

 

(d) The Company has
complied, in all material respects, with all applicable employment laws, policies, procedures and agreements relating to employment,
and terms and conditions of employment. The Company has paid in full to all of its respective employees and consultants all wages,
salaries, commissions, bonuses, benefits and other compensation due and payable to such employees or consultants on or prior to
the date of this Agreement. The Company has complied in all material respects with the applicable laws relating to the proper withholding
and remittance to the proper tax and other authorities of all sums required to be withheld from employees or persons deemed to
be employees under applicable laws. To the Company’s knowledge, all persons classified by the Company as consultants or contractors
thereof are correctly classified as such and not as employees for any purpose. All Company’s employees are subject to Section
14 Arrangement under the Israeli Severance Pay Law, 1963 from the commencement date of their employment and on the basis of their
entire salary. The Company’s liability for any obligations to pay any amount of severance payment, pension, accrued vacation,
and other social benefits and contributions, under applicable law or contract, or any other payment of substantially the same nature,
is fully funded by deposit of funds in severance funds, pension funds, managers insurance policies or provident funds (and if not
required to be so funded) adequate provisions have been made in the Company’s Financial Statements;

 

(e) To the Company’s
knowledge, no employee of the Company nor any consultant with whom the Company has contracted, is in violation of any material
term of any employment or engagement contract, assignment agreement, non competition agreement, restrictive covenant or any other
contract or agreement, or is subject to any judgment, decree or order of any court or administrative agency, that would materially
interfere with such employee’s or consultant’s ability to promote the interest of the Company or to comply with its
obligations to the Company (including the obligation to assign intellectual property rights) or that would conflict with the Company’s
business, and the continued employment or engagement of such employee or consultant by the Company will not result in any such
material violation. The Company has not received any notice alleging that any such violation has occurred.

 

(f) The Company is
not a party to, bound by or subject to, and no employee of the Company benefits from, any collective bargaining agreement, collective
labor agreement, extension orders (tzavei harchava) (other than extension orders that apply to all employees in Israel generally),
or other contract or arrangement with a labor union, trade union or other organization or body, to provide benefits or working
conditions beyond the minimum benefits and working conditions required by applicable law. No labor union has requested or has sought
to represent any of the employees, representatives or agents of the Company, nor is the Company aware of any labor organization
activity involving its employees. There is no strike or other labor dispute involving the Company pending or, to the Company’s
knowledge, threatened.

 

2.18 Taxes.
Subject to the provisions of Section 2.18 of the Disclosure Schedule,

 

(a) The Company has
duly and timely filed all tax returns and reports (including information returns and reports) as required by applicable law. Each
such return or report was true and complete in all material respects when filed. None of such returns or reports has been audited
by any taxing authority and the Company has not been advised that any of such returns or reports will be audited. There is no pending
(or threatened by written notice delivered to the Company prior to the date hereof) dispute, examination, audit, claim or other
action concerning any tax or tax return of the Company claimed or raised by any tax authority. Any and all taxes and other charges
due by the Company to any local or foreign tax authorities (including, without limitation, those due in respect of the properties,
income, franchises, licenses, sales or payrolls) have been timely paid. The Company has never had any tax deficiency proposed or
assessed against it and has not executed any waiver of any statute of limitations on the assessment or collection of any tax or
governmental charge. The Company has not incurred any taxes, assessments or governmental charges other than in the ordinary course
of business. The Company has made adequate provisions on the Financial Statements and its books of account for all taxes, assessments
and governmental charges with respect to its business, properties and operations for the applicable period thereof. The Company
is not and have never been subject to tax in any country other than its jurisdiction of incorporation by virtue of being treated
as a resident of or having a permanent establishment or other place of business in that country, and no claim has ever been made
by a tax authority in a jurisdiction where the Company does not file tax returns that it is or may be subject to taxation by that
jurisdiction.

 

    14

     

    

  

(b) The Company has
not made any elections pursuant to the Israeli Income Tax Ordinance [New Version], 1961 (together with the regulations promulgated
thereunder, as amended, the “ITO”). The Company is not subject to any tax ruling nor has it ever applied to
receive any tax determination or ruling.

 

(c) All related party
transactions or agreements to which the Company is a party (including, intercompany agreements) comply with transfer pricing rules
and regulations under applicable law (including, Section 85A of the ITO).

 

(d) The Plan has received
a favorable determination or approval letter from, or is otherwise approved by, the Israeli Tax Authority in accordance with Section
102(b)(2) of the ITO. All options purported to be granted and shares purported to be issued under Section 102(b)(2) of the ITO
were and are in compliance with the applicable requirements of Section 102(b)(2) of the ITO (and any written requirements, regulations
and rules promulgated thereunder).

 

2.19 Governmental
Grants. The Company has not applied, obtained or received any grant, loan, incentives, benefits (including tax benefits), subsidies
or other assistance from any governmental or regulatory authority or any agency, or any international or bilateral fund, institute
or organization or public entities or authorities, including, from the Investment Center of the Ministry of Economy and Industry
of the State of Israel or the National Authority for Technological Innovation (previously known as the Office of the Chief Scientist
of Israel’s Ministry of Economy), nor is the Company an “approved enterprise”, “benefited enterprise”
or “preferred enterprise” within the meaning of the Israeli Encouragement of Capital Investments Law, 1959.

 

2.20 Litigation.
There is no claim, action, suit, proceeding, arbitration, complaint, charge or, to the Company’s knowledge, investigation
pending, or, to the Company’s knowledge, currently threatened against the Company, any of its properties, or any Founder,
officer, director or employee of the Company, including, without limitation, arising out of their employment or board relationship
with the Company or in their capacity as such, or that questions the validity of the Transaction Documents or the right of the
Company to enter into them, or to consummate the transactions contemplated by the Transaction Documents. Neither the Company nor,
to the Company’s knowledge, any of its officers, directors, consultants or employees is a party or is named as subject to
the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the
case of officers, directors or employees, such as would affect the Company). There is no action, suit, proceeding or investigation
by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings
or investigations pending or, to the Company’s knowledge, threatened (or any basis therefor known to the Company) involving
the prior engagement of any of the Company’s employees or the Founders, their services provided in connection with the Company’s
business, any information or technologies allegedly proprietary to any of their former employers or their obligations under any
agreements with former employers.

 

2.21 Related-Party
Transactions. Except as listed in Section 2.21 of the Disclosure Schedule, No Founder, employee, shareholder, officer, or director
of the Company, nor members of their immediate family or affiliates of any of the foregoing: (i) is indebted to the Company, nor
is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them (other than advances for employees’
expense reimbursement in the ordinary course of business); (ii) to the Company’s knowledge, has any direct or indirect interest
in any contract, arrangement or proposed transaction with the Company or its affiliates which is material to the Company or its
business (other than employment relations disclosed to Investor hereunder); or (iii) to the Company’s knowledge, has any
direct or indirect ownership interest in any contract with the Company, or in any firm, corporation or business with which the
Company is affiliated or with which the Company has a business relationship, or that competes with the Company, except for passive
ownership of less than one percent (1%) of the issued and outstanding share capital of any such publicly traded company.

 

    15

     

    

  

2.22 Corporate
Books. The Articles of Association of the Company as in effect immediately prior to the Closing are in the form provided to
Investor. The Company has provided to the Investor accurate and complete copies of the minutes of all meetings, or written consents
in lieu thereof, of directors (and any committee thereof) and shareholders since its incorporation, reflecting, in all material
respects, resolutions passed, enacted, consented to or adopted thereby. The corporate records of the Company have been maintained,
in all material respects, in accordance with all applicable statutory requirements and are complete and accurate in all material
respects.

 

2.23 Insurance.
The Company has no insurance policies, and intends to obtain required insurance policies which are reasonably sufficient in amount
(subject to reasonable deductions) following the Closing to allow it to replace any of its properties that might be damaged or
destroyed and to insure the risks associated with its business and affairs.

 

2.24 No Corrupt
Practices. Neither the Company nor any officer, director, employee or agent purporting to act on its behalf has, directly or
indirectly: (i) made, offered to make, provided or paid any unlawful contributions, gifts, entertainment or other unlawful expenses
to any local or foreign official, political party or official thereof or candidate for political office, or failed to disclose
fully any such contributions in violation of any applicable laws; (ii) made, or offered to make, any payment to any local, state,
federal or any other type of governmental officer or official, or other person charged with similar public or quasi-public duties,
other than payments required or allowed by applicable laws (including, without limitation, the United States Foreign Corrupt Practices
Act of 1977, as amended); (iii) made, or offered to make, any payment to any agent, employee, officer or director of any entity
with which the Company does business for the purpose of influencing such agent, employee, officer or director to do business with
the Company; (iv) engaged in any transactions, maintained any bank account or used any corporate funds, except for transactions,
bank accounts and funds which have been and are reflected in the normally maintained books and records of the Company; or (v) made,
or offered to make, any payment in the nature of criminal bribery or any other payment in violation of any applicable law. Neither
the Company, nor, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation,
voluntary disclosure, investigation, prosecution or other enforcement action related to any anti-corruption laws.

 

2.25 Brokers and
Finders. The Company has no contract, arrangement or understanding with any broker, finder or similar agent with respect to
the transactions contemplated by this Agreement. No commission or compensation in the nature of a finders’ fee shall be payable
by the Company or any of its officers, employees or representatives, in their capacities as such, in connection with the transactions
contemplated by this Agreement.

 

2.26 Disclosure.
No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate
furnished or to be furnished to Investor at the Closing contains any untrue statement of a material fact or, to the Company’s
knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading
in light of the circumstances under which they were made.

 

    16

     

    

 

3. REPRESENTATIONS
AND WARRANTIES OF THE INVESTOR.

 

The Investor hereby
represents and warrants, with respect to itself only, that the following representations are true, correct and complete as of the
date hereof and as of the Closing (as if made on the Closing Date); except, in each case, as to such representations and warranties
that address matters as of a particular date, which are given only as of such date:

   

3.1 Authorization;
Organization. The Investor is duly organized, validly existing and, if applicable, in good standing under the laws of the
jurisdiction in which it has been incorporated and has full power and authority to enter into the Transaction Documents. The Transaction
Documents to which the Investor is a party, when executed and delivered by the Investor, and assuming the due authorization, execution
and delivery by the other parties hereto and thereto, constitute valid and binding obligations of the Investor, enforceable against
the Investor in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’
rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies.

 

3.2 No Conflict;
Consents. The execution, delivery and performance by the Investor of the Transaction Documents to which it is a party and the
consummation of the transactions contemplated by such Transaction Documents do not and will not (a) result in any conflict with,
or a breach or violation, with or without the passage of time and giving of notice, of any of the terms, conditions or provisions
of, or give rise to rights to others (including rights of termination, cancellation or acceleration) under: (i) the governing documents
of the Investor; (ii) any judgment, injunction, order, writ, decree or ruling of any court or governmental authority, domestic
or foreign, to which the Investor is subject; (iii) any material contract or agreement, lease, license or commitment to which the
Investor is a party or by which it is bound; (iv) any applicable law; or (b) require the consent, approval or authorization of,
registration, qualification or filing with, or notice to any person or any federal, state, local or foreign governmental authority
or regulatory authority or agency, on the part of the Investor, which has not heretofore been obtained or made or will be obtained
or made prior to Closing.

 

3.3 Purchase Entirely
for Own Account. The Purchased Shares will be acquired for investment for the Investor’s own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling,
granting any participation in, or otherwise distributing the same. The Investor does not presently have any contract, undertaking,
agreement or arrangement to sell, transfer or grant participation rights to any person with respect to any of the Purchased Shares.
The Investor has not been formed for the specific purpose of acquiring the Purchased Shares.

 

3.4 Disclosure
of Information. The Investor has had an opportunity to discuss the Company’s business, operations, properties, prospects,
technology, plans, management, financial affairs and the terms and conditions of the offering of the Purchased Shares with the
Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however, does not
limit, modify or qualify the representations and warranties of the Company in Section ‎2 of this Agreement or the right of
the Investor to rely thereon. The Investor acknowledges that any projections provided (if any) by the Company are uncertain in
nature, and that some or all of the assumptions underlying such projections may not materialize or will vary significantly from
actual results.

 

3.5 Investment
Experience; Accredited Investor; Non-U.S. Person. The Investor is an investor in securities of companies in the development
stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge
and experience in financial or business matters that it is capable of evaluating and understanding the merits and risks of the
investment in the Purchased Shares.

 

3.6 Restricted
Securities. The Purchased Shares have not been and will not be registered under the Securities Act or any state securities
laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws
or unless an exemption from such registration requirements is available. Investor is aware that the Company is under no obligation
to effect any such registration or to file for or comply with any exemption from registration. The sale and issuance of the Purchased
Shares have not been registered under the Securities Act by reason of a specific exemption from registration which depends upon,
among other things, the accuracy of the Investor’s representations as expressed herein.

 

    17

     

    

  

4. CONDITIONS OF INVESTOR’S
OBLIGATIONS AT CLOSING.

 

The obligations of
the Investor to purchase the Purchased Shares at the Closing are subject to the fulfillment on or before the Closing of each of
the following conditions, unless otherwise waived in writing by the Investor:

 

4.1 Representations
and Warranties. The representations and warranties of the contained in Section ‎2 shall have been true in all respects
on and as if made as of the Closing.

 

4.2 Performance.
The Company shall have performed and complied, in all respects, with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before the Closing.

 

4.3 Delivery of
Documents. All of the documents to be delivered by the Company pursuant to Section ‎1.6, shall have been in a form as attached
to this Agreement, or, if not attached, in a form and substance satisfactory to the Investor and shall have been delivered to the
Investor.

 

4.4 Receipt of
Consents. The Company shall have been obtained at or prior to the Closing Date all consents required to consummate the transactions
herein.

 

4.5 Absence of
Adverse Changes. There shall not have occurred any event, change, effect, condition or circumstance that, when taken individually
or together with any other events, changes, effects, conditions or circumstances, is or is reasonably likely to be adverse to the
business, assets, properties, operations, results of operations or financial condition of the Company.

 

4.6 Restated Articles.
The Restated Articles shall have been duly adopted.

 

4.7 Option Pool.
The ESOP Pool shall have been duly reserved prior to the Closing.

 

5. CONDITIONS OF THE
COMPANY’S OBLIGATIONS AT CLOSING.

 

The obligations of
the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following
conditions, unless otherwise waived in writing by the Company:

 

5.1 Representations
and Warranties. The representations and warranties contained in Section ‎4 shall have been true in all respects on
and as if made as of the Closing.

 

5.2 Payment of
Purchase Price. The Investor shall have delivered to the Company the Investor’s respective portion of the Purchase Price
for the Purchased Shares issued to the Investor at the Closing.

 

6. AFFIRMATIVE COVENANTS
BY THE COMPANY.

 

6.1 Use of Proceeds.
The Company will use the Purchase Price for general working capital purposes substantially in accordance with the Budget, attached
hereto as Exhibit E, as may be amended from time to time by the Board.

 

6.2 Directors
and Officers Insurance. Within thirty (30) days from the Closing, the Company shall purchase a directors and officers liability
insurance policy in an amount of at least US$2,500,000 and upon other terms acceptable to the Investor.

 

    18

     

    

 

6.3 Additional
Engagements. Within thirty (30) days from the Closing, the Company shall conclude and enter into the following agreements:

   

(a) The Company and
a company held by Eli Uzan and others (the “Management Company”) shall enter into a management services agreement,
pursuant to which the Management Company will provide management services in consideration for a monthly fee of NIS 50,000 plus
VAT (the “Consideration”) (the “Services Agreement”). In the event that the Company will
terminate the Services Agreement at any time prior to the end of 3 (three) years from Closing (the “Minimum Term”),
then, (i) if at that time the Company shall have met its Budgetary Objective (as defined below) for such moment in time, then,
it will pay to the Management Company an amount of money equal to the Consideration due during a period of 3 years, and (ii) if
at that time the Company shall not have met its Budgetary Objective for such moment in time, then, it will pay to the Management
Company an amount of money equal to the Consideration due during a period of 1 (one) year. The “Budgetary Objective”
shall be a 10% or more increase in the EBITDA compared to the former year, starting on 2021.

 

(b) The Company and
Screenz Cross Media Ltd. Shall enter into a commercial agreement, based on the principles set out in Schedule 6.3(b).

 

6.4 Filing with
the Israeli Registrar of Companies. As soon as possible following the Closing, and in any event no later than 14 days following
the Closing, the Company shall file all required notices set forth in Section ‎1.6(a)(vii) with the Israeli Registrar of Companies,
including, to the extent required, a translation of the Restated Articles into Hebrew certificated by an officer of the Company
as required by the Companies Law and any regulations promulgated thereunder.

 

6.5 Accounting.
The accountants and auditors of the Company shall be any firm selected by the Investor, in its sole discretion. The Company will
maintain at its main office a system of accounting established and administered in accordance with GAAP consistently applied, which
true records and books of account will be made of all dealings or transactions relating to the affairs of the Company. To the extent
that as a result of the requirements under this Section 6.5, the Company incurs expenses that are greater than US$ 30,000 (the
“Additional Expenses”), at the end of each fiscal year, and subject to the provision by the Company of credible
evidence and calculations, the Investor shall reimburse the Company for such Additional Expenses.

 

7. INDEMNIFICATION.

 

7.1 Effectiveness;
Survival.

 

(a) The Investor has
the right to fully rely upon all representations, warranties and covenants of the Company (as applicable, severally and not jointly,
the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules attached hereto. Unless
otherwise set forth in this Agreement, the representations and warranties of the Company contained in or made pursuant to this
Agreement shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the
Investor.

 

(b) The representations
and warranties of the Company contained in or made pursuant to this Agreement shall survive the execution and delivery of this
Agreement and the Closing until the earlier of: (1) in case of Section ‎2.13 (Intellectual Property), until the
36th months anniversary of the Closing Date; (2) in case of Sections ‎2.1 (Organization), ‎‎2.2
(Capitalization), ‎2.3 (Authorization), ‎2.4 (Valid Issuance of Shares) and ‎2.5
(No Conflict; Consents) (the representations and warranties referred to in this clause (2), collectively, the “Fundamental
Representations”), until the expiration of the applicable statute of limitation period; and (3) other than as set forth
in clause (1) and (2) above, the 24th months anniversary of the Closing Date; in each case, with respect to any theretofore
un-asserted claims as set forth in clause (c) below;

 

provided, however,
that no limitation shall apply to breach of any representation or warranty which constitutes fraud or willful misrepresentation
by the Company (“Fraud”). The applicable survival period shall be referred to, as applicable, as the “Claims
Period”.

 

    19

     

    

  

(c) Except for Fraud,
the Company shall not have any liability with respect to any breach of representation and warranty, unless a claim is made hereunder
prior to the expiration of the Claims Period for such representation and warranty, in which case such representation and warranty
shall survive as to that claim until the claim has been finally resolved.

 

(d) It is the intention
of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations and warranties,
and this Section 7.1 constitutes a separate written legally binding agreement among the parties hereto in accordance with the provisions
of Section 19 of the Israeli Limitation Law, 1958.

 

7.2 Indemnification.

 

(a) Indemnifiable
Losses. The Indemnitor shall indemnify the Investor (including its directors and officers) (each, an “Indemnitee”)
against, and hold each Indemnitee harmless from all claims, actions, suits, settlements, damages, expenses (including, reasonable
legal costs and expenses), losses, or costs sustained or incurred by such Indemnitees (collectively, “Losses”)
resulting from, or arising out of, a breach or misrepresentations of any the Indemnitor’s representations, warranties or
covenants made in this Agreement, subject to the limitations in this Section 7.

 

(b) Limitations.
The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations, notwithstanding
anything to the contrary in this Agreement, but in to any other limitation or condition contained herein; provided, however,
no limitation shall apply to Fraud:

 

(i) The Indemnitor’s
liability shall be limited to direct damages only of the Indemnitees.

 

(ii) Other than in
respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate of Losses
equal or exceeds US$20,000, in which case indemnification shall be made from the first dollar amount.

 

(iii) The Indemnitor’s
liability shall be limited with respect to the Investor to the sum of the Purchase Price.

 

(c) Claims Notice;
Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder it shall give the
Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable detail the
facts and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor informed,
in all material respects, with respect thereto. In the event that such Claims Notice results from a third party claim against the
Indemnitee, such Indemnitee shall promptly upon becoming aware of the commencement of proceedings by such third party provide the
Indemnitor with the Claims Notice and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s
expense) with counsel mutually satisfactory to the parties; provided, however, that the Indemnitees shall have the right
to retain their own counsel, at the reasonable expense of the Indemnitor, and within the indemnification limitations herein, if
representation of all parties by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing
interests between the parties in such proceeding. Failure of the Indemnitees to give prompt notice or to keep it informed, as provided
herein, shall not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is actually
and materially prejudiced by such failure. The Indemnitor shall not be liable nor shall it be required to indemnify or hold harmless
the Indemnitee in connection with any settlement effected without its consent in writing, which shall not be unreasonably withheld
or delayed.

 

    20

     

    

  

(d) Notwithstanding
the forgoing, in the event that as a result of a breach by the Company of any of the representations and warranties set forth in
Sections 2.2 or 2.4 above, in a manner that the percentage holdings of the Investors in the Company as of immediately after the
Closing shall be lower than the percentage they would have been entitled to pursuant to this Agreement had such breach not occurred
(i.e. to the extent that as a result of a breach of the representations and warranties set forth in Sections 2.2 or 2.4 the Company
is obligated to issue additional shares or convertible securities) (a “Dilution”), then, in lieu of the indemnification
pursuant to Section 7, the Investors shall be issued by the Company additional Ordinary Shares for no additional consideration,
in such amount that following the issuance thereof, each Investor’s percentage ownership in the Company, on a Fully Diluted
Basis, shall be equal to its percentage ownership immediately prior to such Dilution.

 

(e) Notwithstanding
the forgoing, the Investor may elect, in its sole discretion, in lieu of the indemnification pursuant to Section 7, to receive
such additional number of Ordinary Shares, for no additional consideration, as is determined by dividing the amount of Losses by
the Fair Market Value (as defined and to be determined as set forth below).

 

The “Fair Market
Value” of one Ordinary Share at the time of payment shall be determined by Investor and the Company (by decision of the directors
of the Company excluding the Medigus Directors); provided, however, that if the Investor and the Company cannot agree on the fair
market value of the Ordinary Shares, the fair market value shall be determined by calculating the average ratio of the market cap
to EBIDTA (as published on the then most-recent annual audited financial statements) of two public companies in the industry of
the Company (which, unless otherwise mutually agreed by Investor and the Company, shall be Live Nation Worldwide, Inc. and CTS
Eventim AG) and multiplying such ration by the Company’s EBIDTA (as published on the then most-recent annual audited financial
statements of the Company).

 

(f) Sole Remedy.
The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall be the exclusive remedy
available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision does not limit the
right to seek specific performance, a restraining order or injunctive relief with respect to any provision of this Agreement.

 

8. MISCELLANEOUS.

 

8.1 Further Assurances.
Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be necessary to
carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.

 

8.2 Entire Agreement.
This Agreement (including the exhibits and schedules hereto), the Restated Articles and the other Transaction Documents constitute
the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and supersede all
prior agreements and understandings, both written and oral, among any of the parties hereto, with respect to the subject matter
hereof (with no concession being made as to the existence of any such prior agreements or understandings).

 

8.3 Amendment;
Waiver. Except as explicitly set forth herein, any term of this Agreement may be
amended only with the written consent of the Company, and the Investor. The observance of any term hereof may be waived (either
prospectively or retroactively and either generally or in a particular instance) only by the prior written consent of the party
against which enforcement of such waiver shall be sought. Any amendment or waiver effected in accordance with this Section 8.3
shall be binding upon the Investor and the Company.

 

    21

     

    

 

8.4 Assignment;
Successors and Assigns. None of the rights, privileges or obligations set forth in, arising under, or created by this Agreement
may be assigned or transferred by the Investor, without the prior written consent of the Company; except that no such consent shall
be required after the Closing in case of an assignment of this Agreement along with the transfer of Purchased Shares from the Investor
to the Investor’s Permitted Transferee (as is defined in the Restated Articles) and the assumption in writing by such Permitted
Transferee of the representations, warranties, covenants and obligations arising under this Agreement, as the Investor hereunder.
In such case, the Investor and the Permitted Transferee shall deliver to the Company a notice, in a form reasonably acceptable
to the Company, notifying and representing to the Company the foregoing. The Company shall be permitted to assign this Agreement
or any and all of its rights, privileges or obligations set forth in, arising under, or created by this Agreement to its successors
and assigns (including to a purchaser, successor or assignor of all or substantially all of its assets) after the Closing, subject
to the assumption by such successors and assigns of this Agreement or any and all of its rights, privileges or obligations hereunder.
Subject to the foregoing, the terms and conditions of this Agreement shall inure to the benefit of, and be binding upon, the respective
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other
than the parties hereto any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.

 

8.5 Governing
Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with to the laws of the State of Israel,
disregarding its conflict of laws rules. Any dispute arising under or in relation to this Agreement shall be resolved exclusively
in the competent court located in Tel Aviv-Jaffa, Israel and each of the parties hereby irrevocably submits to the exclusive jurisdiction
of such court. Each of the parties hereto (i) consents to submit itself to the exclusive jurisdiction of the abovementioned courts
in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii) agrees that it shall
not attempt to deny or defeat such jurisdiction by motion or other request for leave from the abovementioned court, (iii) agrees
that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other
than the abovementioned court, and (iv) irrevocably consents to service of process in the manner provided by Section 8.6 or as
otherwise provided by applicable law.

 

8.6 Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt, or (i) when delivered, if sent by personal delivery to the party to be notified, (ii)
when sent, if sent by electronic mail or facsimile (with electronic conformation of delivery) on a business day and during normal
business hours of the recipient, and otherwise on the first business day in the place of recipient, (iii) five (5) business days
after having been sent, if sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business
day after deposit with an internationally recognized overnight courier, freight prepaid, specifying next business day delivery,
with written confirmation of receipt. All communications shall be sent to the respective parties at their address or contact details
as set forth below, or to such address or contact details as subsequently modified by written notice given in accordance with this
Section 8.6, or, in the case of the Investor, as used for purposes of sending shareholders’ notices by the Company.

 

	If to the Company:	Eventer Technologies Ltd.
	 	Attention: Eli Uzan, Director
	 	Telephone: 054-314-4558
	 	E-mail: eli@scrnz.com
	 	 
	If to the Investor:	as set forth on Exhibit A

 

8.7 Delays or
Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any
party to this Agreement upon any breach or default of any other party under this Agreement, shall impair any such right, power
or remedy of such non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth
in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall
be cumulative and not alternative.

 

    22

     

    

  

8.8 Interpretation.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement. The words “include”, “includes” and “including” shall be deemed to be followed
by the phrase “without limitation”. Unless the context requires otherwise, the words “herein”, “hereof”
and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety, and not
to any particular provision hereof, and all references herein to Sections shall be construed to refer to Sections to this Agreement.
Reference to “governmental authorities” (or similar terms) shall include any: (a) nation, principality, state, commonwealth,
territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign or
other government, (c) governmental, quasi-governmental or regulatory body of any nature, including any governmental division, subdivision,
department, agency, bureau, branch, office, commission, council, board, instrumentality, organization, unit, or body, or (d) court,
public or private arbitrator or other public tribunal. Reference to a “person” shall mean any individual, corporation,
partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, estate, unincorporated organization,
governmental authority or other entity, including, any party to this Agreement. Any reference to a “day” or a number
of days (without explicit reference to “business days”) shall be interpreted as a reference to a calendar day or number
of calendar days, and if any action is to be taken or given on or by a particular calendar day, and such calendar day is not a
business day, then such action may be deferred until the first business day thereafter (where “business day” shall
mean any day on which banking institutions in Tel-Aviv-Jaffa, Israel are generally open to the public for conducting business and
are not required by law to close). For the purposes of this Agreement, all indebtedness, liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same person, or such person and its affiliates (including persons
the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual
minimum dollar amounts indicated herein.

 

8.9 Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be enforceable in accordance with its terms and interpreted so as to
give effect, to the fullest extent consistent with and permitted by applicable law, to the meaning and intention of the excluded
provision.

 

8.10 Counterparts.
This Agreement and any Transaction Document may be executed in one or more counterparts, all of which together shall constitute
one and the same instrument, binding and enforceable against the parties so executing the same; it being understood that all parties
need not sign the same counterpart. Counterparts may also be delivered by facsimile or email transmission (in pdf format or the
like, or signed with docusign, e-sign or any similar form of signature by electronic means) and any counterpart so delivered shall
be sufficient to bind the parties to this Agreement or any other Transaction Document, as an original.

 

-
Signature Pages Follow -

 

    23

     

    

 

IN WITNESS WHEREOF,
the parties have executed this SHARE PURCHASE AGREEMENT to be executed as of the date first written above.

  

COMPANY:

 

	 	Eventer Technologies Ltd.
	 	 	 
	 	By:	/s/ Eli Uzan
	 	Name:	Eli Uzan
	 	Title: 	Chairman

  

	 	By:	/s/ Julien Azoulay
	 	Name:	Julien Azoulay
	 	Title:	Chief Executive Officer

    

     

     

    

  

IN WITNESS WHEREOF, the
parties have executed this SHARE PURCHASE AGREEMENT as of the date first written above.

 

INVESTOR:

 

	 	Medigus Ltd.
	 	 
	 	By:	/s/ Eli Yoresh
	 	Name:	Eli Yoresh
	 	Title:	Chairman

 

	 	By:	/s/ Liron Carmel
	 	Name:	Liron Carmel
	 	Title:	Chief Executive Officer

   

     

     

    

  

Exhibit A

 

Investor and Purchased
Shares at the Closing

 

	Name of Investor	 	Contact Details	 	Investment Amount	 	 	Purchased Shares	 
	Medigus Ltd.	 	Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel
 Attention: Liron Carmel
 Telephone: +972-72-260-2200
 Email: liron.carmel@medigus.com
  
 With a mandatory copy (which shall not
 constitute notice) to:
 Meitar Law Offices
 Attention: Dr. Shachar Hadar, Adv.
 Telephone: 03-610-3961
 Facsimile: 03-610-3111
 Email: shacharh@meitar.com
	 	US$	750,000	 	 	 	325,270	 

 

     

     

    

  

Exhibit B

 

Capitalization Table

 

[***]

 

     

     

    

  

Exhibit C

 

Restated Articles

 

[***]

 

     

     

    

  

Exhibit D

 

Share Exchange Option
Agreement

 

[***]

 

     

     

    

  

Schedule 1.1

 

Adjustment

 

[***] 

 

     

     

    

 

Schedule 1.4

 

Milestone Conditions

 

[***]

 

     

     

    

 

Schedule 1.5(a)(i)

 

Board Action

 

[***] 

 

     

     

    

 

Schedule1.5(a)(ii)

 

Shareholders Action

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(v)

 

Share Certificate Form

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(vi)

 

Shareholders Register

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(vii)

 

Registrar of Companies
Notices

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(xi)

 

Indemnification Agreement

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(xi)

 

Information Rights
Agreement

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(xii)

 

Officer’s Certificate

 

[***] 

 

     

     

    

 

Schedule 1.5(a)(xiii)

 

Revolving Promissory
Note

 

[***]

 

     

     

    

  

Schedule 6.3(b)

 

Principles of Engagement
with Screenz Cross Media

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]